University of Louisville

ThinkIR: The University of Louisville's Institutional Repository
Electronic Theses and Dissertations
12-2014

Post-transcriptional regulation of the Type IIA sodium-phosphate
cotransporter by parathyroid hormone.
Rebecca Dale Murray
University of Louisville

Follow this and additional works at: https://ir.library.louisville.edu/etd
Part of the Physiology Commons

Recommended Citation
Murray, Rebecca Dale, "Post-transcriptional regulation of the Type IIA sodium-phosphate cotransporter by
parathyroid hormone." (2014). Electronic Theses and Dissertations. Paper 1749.
https://doi.org/10.18297/etd/1749

This Doctoral Dissertation is brought to you for free and open access by ThinkIR: The University of Louisville's
Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized
administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of
the author, who has retained all other copyrights. For more information, please contact thinkir@louisville.edu.

POST-TRANSCRIPTIONAL REGULATION OF THE TYPE IIA SODIUMPHOSPHATE COTRANSPORTER BY PARATHYROID HORMONE

By
Rebecca Dale Murray
B.A., Northwestern University, 2009
M.S., University of Louisville, 2013

A Dissertation
Submitted to the Faculty of the
School of Medicine of the University of Louisville
in Partial Fulfillment of the Requirements
for the Degree of

Doctor of Philosophy

Department of Physiology & Biophysics
University of Louisville
Louisville, KY

December 2014

Copyright 2014 by Rebecca Dale Murray

All rights reserved

POST-TRANSCRIPTIONAL REGULATION OF THE TYPE IIA SODIUMPHOSPHATE COTRANSPORTER BY PARATHYROID HORMONE

By
Rebecca Dale Murray
A Dissertation Approved on

November 24, 2014

by the following Dissertation Committee:

_________________________________
Eleanor D. Lederer, M.D.
_________________________________
Syed J. Khundmiri, Ph.D.
_________________________________
Barbara J. Clark, Ph.D.
_________________________________
Cynthia J. Miller, Ph.D.
_________________________________
Jeff C. Falcone, Ph.D.
_________________________________
Irving G. Joshua, Ph.D.
ii

DEDICATION

This dissertation is dedicated to my parents,
Paul and Meridith Murray,
for pancakes and applesauce at the Mariann.

iii

ACKNOWLEDGEMENTS

The work within this dissertation represents the culmination of several years of
training, during which time I have been extremely fortunate to receive help from many
talented and supportive individuals. I would like to thank Nina Lesousky, Sarah Salyer,
and Francesca Kingery for helping me to find my feet in the lab. I would also like to
thank my committee members for their support and sage advice, and in particular I would
like to thank Dr. Clark for committing to a multi-year collaboration with a graduate
student. I am very much indebted to Jalal for his constant guidance and support, and for
putting up with a very sassy graduate student these past four years. Lastly I would like to
thank Dr. Lederer, not only for agreeing to mentor a graduate student with no prior
research experience, but for providing me with an outstanding predoctoral training full of
intellectual challenges, well-timed humor, and endless support of my current and future
endeavors.

iv

ABSTRACT
POST-TRANSCRIPTION REGULATION OF THE TYPE IIA SODIUM-PHOSPHATE
COTRANSPORTER BY PARATHYROID HORMONE
Rebecca D. Murray
November 24, 2014

The type IIa sodium-phosphate cotransporter (Npt2a) is expressed in the apical
membrane of the renal proximal tubule and is responsible for the reabsorption of the
majority of the filtered load of phosphate. Parathyroid hormone (PTH) is secreted by the
parathyroid gland in response to a decrease in serum calcium or an increase in serum
phosphorus, and acutely induces phosphaturia through the rapid stimulation of
endocytosis of Npt2a and its subsequent lysosomal degradation. Chronic PTH stimulation
leads to sustained phosphaturia, but the mechanisms for the chronic regulation of Npt2a
by PTH remain unclear. We hypothesize that PTH decreases Npt2a mRNA levels as a
mechanism for inducing chronic phosphaturia. We address this hypothesis within three
specific aims. The first specific aim addresses the kinetics and mechanisms of the PTHstimulated decrease in Npt2a mRNA expression. The second aim details the signaling
pathways involved in PTH-mediated downregulation of Npt2a mRNA. Lastly, the third
aim characterizes the PTH-responsive phosphoproteome of the proximal tubule, and how
changes in the expression and phosphorylation of RNA-binding proteins may affect
Npt2a mRNA stability.
v

In Aim 1, we found that PTH decreases Npt2a steady-state mRNA levels with a
50% loss in 2.2h compared to 8.6h in the absence of PTH. This effect is posttranscriptional, and is dependent on both transcription and translation. In Aim 2, we
determined that PTH destabilizes Npt2a mRNA through both PKA- and PKC-dependent
mechanisms. The rapid initial decline in Npt2a mRNA levels corresponds to and appears
to be dependent on early PTH-stimulated PKA activation. In contrast, PTH-stimulated
PKC activation occurs more gradually over several hours and likely contributes to the
latter phase of Npt2a mRNA destabilization. Finally, in Aim 3, we found that PTH alters
the phosphorylation status of almost 1200 proteins in the proximal tubule, including 68
RNA-binding proteins (RBPs). Two of those RBPs, KHSRP and Roquin-2, bind to Npt2a
mRNA, and their expression varies inversely with Npt2a mRNA levels. From these
studies, we conclude that PTH-mediated Npt2a mRNA destabilization likely occurs
through PKA- and PKC-dependent modulation of RBP expression and activity, and that
KHSRP and Roquin-2 are potential mediators of the PTH response.
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CHAPTER I
INTRODUCTION

“Where there’s life there’s phosphorus”

Since the initial isolation of adenosine triphosphate from muscle extracts in 1929,
phosphate has been at the heart of physiology. The aforementioned quote is known as
Todd’s Hypothesis, after the biochemist Alexander Todd (1907-1997) who was the first
to chemically synthesize the ATP molecule in 1948, for which he later won the Nobel
Prize in 19581. The phosphate ester bond is a uniquely flexible chemical bond, with the
ability to form extremely stable bonds capable of enduring millions of year (DNA) as
well as extremely transient bonds that last mere milliseconds. In the years following the
discovery of ATP, scientists have uncovered numerous biological processes in which
phosphate is a critical element. At the underpinning of life as we know it, phosphate is
essential in formation of deoxy- and ribonucleic acids2. Apart from being an integral part
of the genetic code, the second major function of phosphate within the body is to provide
whole organism structure through the development and maintenance of the skeleton. In
the form of ATP, phosphate is also an essential component of the ubiquitous energy
currency for cellular metabolism3–5. Intracellular signaling and secondary messenger
cascades are heavily reliant on the use of phosphate as an on- or off-switch in the
regulation of enzymatic activity and protein function6.
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Within the body, phosphate is a ubiquitous mineral, and is present as inorganic
phosphate, the vast majority of which is located within bone and teeth (85%), with the
bulk of the remainder being found in soft tissues (14.3%); interstitial fluid, plasma, and
red blood cells each account for less than three-tenths of a percent of the total body
phosphate content7. In addition to the major physiological functions previously
mentioned, phosphate also plays several other roles within the body. Divalent phosphate
(HPO42-) is an important physicochemical buffer, maintaining pH balance during states of
acidosis. It provides structure not only at the macromolecular level in the form of bone
mineralization and formation, but also at the cellular level, providing organization and
compartmentalization through the stability and amphipathic nature of phospholipids.
Phosphate also aids in oxygen transport through the interaction of 2,3-diphosphoglycerate
with hemoglobin7. As a crucial biological mineral, phosphate and the processes
underlying its homeostasis remain significant areas of research.

Pathophysiology of phosphorus
The fact that total body phosphate homeostasis is crucial for cardiovascular health
is one of the most significant findings of the last two decades8–10. Dysregulation of
phosphate homeostasis, including both hyperphosphatemia and hypophosphatemia, can
result in severe pathophysiological conditions. Normal clinical values for serum
phosphorus have been defined as 3.4 to 4.5 mg/dL11. Even mild hyperphosphatemia with
serum values of 5.5 mg/dL or greater correlate with a statistically significant increase in
the risk of death from cardiovascular and renal diseases12. Increased serum phosphorus
accompanying chronic kidney disease is associated with such cardiovascular
complications as vascular calcification and toxicity13,14. In addition to elevated serum
2

phosphorus leading to increased precipitation of calcium-phosphate deposits within the
body, research indicates that the presence of excess phosphate itself can be detrimental to
cell function, particularly in cardiovascular cells. Vascular smooth muscle cells cultured
in a high phosphorus medium displayed upregulated expression of bone-promoting
differentiation markers that facilitate extracellular matrix calcification15,16. Phosphate has
been implicated as a pro-aging factor6, producing not only vascular pathologies such as
ectopic calcification and arteriosclerosis, but also contributing to the development of
COPD, chronic kidney disease, and hearing loss. Aside from cardiovascular
complications, it is thought that diets chronically high in phosphorus strongly contribute
to bone disorders in aging17. Accumulation of phosphate has even been implicated in the
development of muscle fatigue during prolonged exercise18.
Just as high serum phosphorus produces increased cardiovascular morbidity and
mortality, too little phosphorus can produce pathologies just as detrimental.
Hypophosphatemia can have severe cardiovascular repercussions including vasodilation,
hemolysis, and cardiac failure19. Additionally, many bone diseases are attributed to
hypophosphatemia. Perhaps most notably, the hereditary skeletal disorder autosomal
dominant hypophosphatemic rickets results from renal phosphate wasting, producing
severe bone malformation20. Other bone diseases also resulting from hypophosphatemia
include X-linked hypophosphatemia as well as hereditary hypophosphatemic rickets with
hypercalciuria. Phosphate is a crucial component of the bone mineral hydroxyapatite, and
hypophosphatemia not only causes decreased bone mineralization and fragility but also
pain and growth retardation21. With so many roles in the body and so many potential
pathologies from the dysregulation of phosphate, its maintenance and regulation thus
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represent a crucial component of cardiovascular and bone health, with serious
implications for clinical morbidity and mortality.

Determinants of serum phosphorus
Total body phosphate homeostasis is tightly maintained through a complex axis
involving the intestines, kidneys, and bones. While the minimum daily dietary
requirements for phosphorus are approximately 20 mmol/day7, the Western diet typically
contains a much higher amount than stipulated by metabolic needs. In adults, serum
phosphorus levels result from a combination of dietary intake, bone modeling, and kidney
excretion rates, the last of which is the most crucial determinant of serum phosphorus.
Dietary phosphate can be obtained from all natural foods, with particular abundance in
protein-rich food as well as cereal grains2. Phosphorus obtained from animal sources is
more bioavailable and more readily absorbed than phosphate obtained from plant
sources22. In more recent years, dietary loads of phosphate have increased through the
heavy reliance of the food industry on phosphate-rich food additives to preserve food
shelf life22. In the steady state, however, the amount of phosphate absorbed from the diet
is balanced by the amount of phosphate excreted by the kidney.
In the gut, absorption of dietary phosphate into the circulation occurs through
paracellular pathways and through transcellular pathways mediated primarily by the type
IIb sodium-phosphate cotransporter (Npt2b), expressed in the apical membrane of the
duodenum and early jejunum17. While Npt2b expression is known to be regulated by
intestinal phosphate content, the specific mechanisms governing regulation of intestinal
phosphate transport remains poorly understood. In addition to the contribution of the gut
to phosphate homeostasis, bone also plays a major role in phosphate homeostasis, as the
4

hydroxyapatite matrix serves as a critical pool of phosphorus and calcium reserves. Adult
bones undergo constitutive remodeling, with phosphate and calcium cycling into and out
of the bones and circulation as osteoclastic bone resorption is countered by osteoblastic
bone formation23. The flux of phosphate into and out of bone is normally balanced in the
adult, and thus serum phosphorus levels are mostly determined by the rate of renal
excretion.
In the kidney, approximately one-fifth of renal plasma flow is filtered into
Bowman’s space. This renal ultrafiltrate then enters the nephron, wherein water and
solutes will either be reclaimed back into the circulation, or pass through to be excreted in
the final urine. A small solute, phosphate is freely filtered at the glomerulus, and its
reabsorption within the nephron occurs almost exclusively in the proximal tubule24.
Phosphate does not undergo secretion within any segment of the nephron, and thus rates
of renal phosphate excretion are dependent on the rate of phosphate reabsorption from the
ultrafiltrate of the glomerulus. The proximal tubular transport maximum for phosphate
reabsorption is directly related to the abundance of phosphate transporters expressed
within the apical membrane. Once the transport maximum is reached, any excess filtered
phosphate will end up in the final urine. Phosphate is reclaimed from the ultrafiltrate
through secondary-active transport coupled to the movement of sodium down its
concentration gradient, which allows for entry of phosphate from the tubule lumen into
the tubular epithelial cell. Reabsorption of phosphate back into the bloodstream is
achieved by phosphate exiting the cell across the basolateral membrane through unknown
mechanisms.

5

Contribution of phosphate transporters to renal phosphate reabsorption
Mammalian phosphate transport is accomplished by two families of secondaryactive sodium-coupled phosphate transporters: SLC20 and SLC34. The SLC20 family is
comprised of PiT-1 (SLC20A1) and PiT-2 (SLC20A2). PiT-1 and PiT-2 mRNAs are
ubiquitously expressed in both murine and human tissue, and they are thought to serve a
housekeeping function of providing phosphate for intracellular metabolic needs25,26.
Within the kidney, although expression of both PiT-1 and PiT-2 has been found, only
PiT-2 has been identified in the apical membrane of the proximal tubule27.
The SLC34 family is comprised of Npt2a (SLC34A1) and Npt2c (SLC34A3).
Both Npt2a and Npt2c are expressed in the apical membrane of the proximal tubule, with
Npt2a expression seen throughout the proximal tubule, while Npt2c expression exhibits
heavier expression in the early segments of juxtaglomerular proximal tubules. Npt2a is an
electrogenic transporter, cotransporting three sodium ions and one divalent phosphate ion
into the cell (3 Na+:1 HPO42-), whereas Npt2c is electroneutral, coupling the entry of two
sodium ions and one divalent phosphate ion (2 Na+:1 HPO42-). Both Npt2a and Npt2c are
the primary mediators of proximal tubule reclamation of filtered phosphate with PiT-2
contributing only a small fraction to overall phosphate reabsorption20,28,29.
In rodents, the type IIa sodium-phosphate cotransporter (Npt2a) has been
identified as the transporter responsible for the majority of phosphate reabsorption,
accounting for up to 80% of brush-border phosphate transport30–32. Studies in mice
support a preeminent role for Npt2a in contributing to overall phosphate homeostasis, as
Npt2a knockout mice not only display significant phosphate wasting, but they also
develop hypercalciuria with tubular and interstitial calcium-phosphate deposits, and
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display developmental skeletal abnormalities33–35. Ablation of the Npt2c gene in mice
does not elicit a hypophosphatemic phenotype, with no apparent disturbances in calcium
or phosphate homeostasis36. Studies of protein dynamics in the proximal tubule show
that in response to PTH, Npt2a is endocytosed and sent to the lysosomes for degradation,
whereas Npt2c is endocytosed but escapes lysosomal degradation, which suggests that
control of Npt2a expression may be more important for rapid and sustained changes in
proximal tubule phosphate reabsorption37.
The contribution of the renal phosphate transporters to overall phosphate
homeostasis may be species-specific, however. Clinical syndromes associated with Npt2a
and Npt2c gene mutations suggest that Npt2c expression and function may be more
important for total phosphate homeostasis than Npt2a in humans. Loss-of-function
mutations in the human Npt2c gene have been identified as the cause of hereditary
hypophosphatemic rickets with hypercalciuria and accompanying nephrolithiasis renal
phosphate wasting6,38. In contrast, human Npt2a mutations were found to be associated
with a considerably milder phenotype of osteoporosis and nephrolithiasis39,40. However,
recent clinical reports suggest a more significant role for Npt2a expression and function
in human phosphate homeostasis than previously thought. Magen et al.41 reported a
clinical case of autosomal recessive hypophosphatemic rickets with renal Fanconi’s
Syndrome secondary to an Npt2a loss-of-function genetic mutation. Likewise, Rajagopal
et al.42 and Kenny et al.43 both reported case studies of mutations in the Npt2a gene that
resulted in phenotypes of renal phosphate wasting with resultant hypercalcemia,
hypercalciuria, and hypophosphatemia. While these clinical reports suggest that the
contribution of specific renal phosphate transporters to overall phosphate homeostasis
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may be more nuanced than previously recognized, they provide evidence and support for
Npt2a as an important determinant of serum phosphorus, as well as a critical target of
regulators of renal phosphate reabsorption.

Regulation of serum phosphorus
The maintenance of serum phosphate is dependent on the rate of its reabsorption
in the kidney, which is subject to strict regulation by a host of factors, including diet and
hormones. Npt2a expression and function are determined by physiologic regulators of
serum phosphorus, including parathyroid hormone (PTH), one of the major phosphaturic
hormones34. The amount of phosphate in the diet regulates phosphate reabsorption in the
kidney, independent of changes in serum phosphorus, as low-phosphate diets upregulate
proximal tubular phosphate reabsorption prior to any changes in serum phosphorus44.
Apart from dietary regulation, phosphate reabsorption is also modulated by a host of
hormonal factors. Several factors that increase renal phosphate reabsorption include
growth hormone, insulin-like growth factor 1, insulin, thyroid hormone, and
stanniocalcin. These factors, however, play a minor role in phosphate homeostasis as
compared to the major hormonal regulators of renal phosphate reabsorption – PTH,
fibroblast growth factor 23 (FGF23), and vitamin D6,45.
PTH is an 84-amino acid peptide hormone that is released from the parathyroid
glands in response to either decreased serum Ca2+ or increased serum Pi46. In bone, PTH
stimulates osteoclastic activity indirectly through its effect on osteoblast secretion of
paracrine factors2,47. As shown in Figure 1, bone resorption as a result of PTH stimulation
releases Ca2+ and Pi into the circulation. In the proximal tubule, PTH upregulates 1α-
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hydroxylase expression, which enhances production of 1,25-dihydroxy-vitamin D,
promoting increased calcium absorption in the gut48. In the process of releasing calcium
from bone, phosphate stores also become liberated. To excrete the excess phosphate and
preserve the newly restored serum calcium level, PTH exerts a phosphaturic effect in the
FIGURE 1

Figure 1: Regulation of serum Ca2+ and Pi by PTH. Low serum Ca2+ stimulates the
release of PTH from the parathyroid gland. PTH acts on the bone to increase bone
resorption, releasing Ca2+ and HPO42- into the bloodstream. At the kidney, PTH increases
Ca2+ reabsorption and decreases HPO42- reabsorption, maintaining the elevated serum
Ca2+ from the resorption of bone. Vitamin D becomes activated in the kidney by 1αhydroxylase, leading to increased Ca2+ absorption from the gut. The restored serum Ca2+
provides a negative feedback signal to the parathyroid glands, discontinuing the release
of PTH.
9

kidney to decrease the reabsorption of phosphate from the plasma ultrafiltrate, while
simultaneously increasing calcium reabsorption in the distal tubule to sustain the
elevation in serum calcium7,49. As serum PTH levels increase, the renal transport
maximum for phosphate decreases50, which is accomplished through the downregulation
of both of the major renal phosphate transporters, Npt2a and Npt2c51.
FGF23 is secreted from the bone and is another potent phosphaturic hormone that
in conjunction with Klotho decreases the renal transport maximum for phosphate by
decreasing the abundance of Npt2a and Npt2c, as well as PiT-2, in the BBM of the
proximal tubule52. Klotho is the co-receptor for FGF23, and also circulates as an
endocrine factor to promote anti-aging systemic effects54. FGF23 exerts its
hypophosphatemic effects independent of and synergistically with PTH53, and plays a
prominent role throughout the development of chronic kidney disease (CKD), as FGF23
expression increases exponentially with the progressive decline of kidney function and
resultant increase in serum phosphate54. Consistent with these effects, FGF23overexpressing mice display hypophosphatemia with decreased transcript and protein
expression of Npt2a55. Conversely, mice with FGF23 gene ablation display increased
serum phosphate, increased apical expression of Npt2a, and an accompanying increase in
the renal phosphate transport maximum53. Distal-tubule-specific deletion of Klotho also
produces a phenotype of hyperphosphatemia with abundant Npt2a BBM expression56.
However, the actions of FGF23 on Npt2a expression are distinct from the actions of PTH,
as PTH-induced phosphaturia is elicited through PKA- and PKC-dependent pathways,
whereas FGF23-mediated phosphaturia occurs via MAP kinase activation57,58.
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Additionally, PTH appears to be a calcium-centric hormone, with secondary effects on
phosphate homeostasis, whereas FGF23 is more phosphate-centric.
While the actions of PTH and FGF23 on proximal tubular phosphate reabsorption
are direct and relatively straight-forward, the actions of vitamin D on phosphate
reabsorption, and Npt2a in particular, are complex. Acutely, vitamin D appears to
stimulate phosphate reabsorption by increasing expression of Npt2a through upregulation
of Npt2a promoter activity in a cell-specific manner, although this action appears to have
a weak direct influence on phosphate transport59. Rather, vitamin D appears to play a
more important role in overall phosphate homeostasis by modulating the
FGF23/Klotho/PTH bone-endocrine axis6. PTH stimulates the formation of active
vitamin D, which, in a negative feedback loop, suppresses further PTH release from the
parathyroid glands60,61. Vitamin D also increases FGF23 expression, which decreases
renal 1α-hydroxylase expression in addition to promoting phosphaturia62. Despite vitamin
D’s direct and indirect actions in the proximal tubule to increase apical membrane
phosphate transport, chronic exposure to vitamin D has actually been shown to decrease
Npt2a expression synergistically with PTH, likely in response to increased phosphate
release from increased bone turnover63.
PTH and FGF23 are the most prominent regulators of serum phosphorus,
although other important physiological factors have also been shown to play a more
minor role in phosphate homeostasis. Secreted frizzled-related protein 4 (Sfrp4) has been
implicated as an acute downregulator of Npt2a expression in the proximal tubule, but
genetic ablation studies were unable to show a chronic physiologically-relevant role of
this protein in overall phosphate homeostasis64. Estrogen has phosphaturic actions that
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induces phosphate wasting through the downregulation of Npt2a mRNA and protein
expression, but produces no effect on the expression of either Npt2c or PiT-25. Other
regulators of serum phosphate with less dramatic effects on renal phosphate transport
include dopamine, PTH-related-peptide, calcitonin, atrial natriuretic peptide, epidermal
growth factor, and glucocorticoids53,65. While these and other factors regulate renal
phosphate transport, PTH remains a critical determinant of phosphate reabsorption within
the proximal tubule, and serves as an important hormonal regulator of proximal tubule
function.

Effects of PTH on proximal tubule ion transport and metabolism
The effects of PTH on the proximal tubule are not limited to phosphate transport
alone. As shown in Figure 2, PTH regulates several ion transporters and metabolic
pathways. PTH stimulates gluconeogenesis through the actions of adenylyl cyclase66,67,
as well as ammoniagenesis through the increased catabolism of glutamate68. In the
kidney, reabsorption of filtered bicarbonate is dependent on sodium-hydrogen exchange
across the apical membrane of the proximal tubule, a process that is also decreased by
PTH through the decreased expression and activity of the sodium/hydrogen exchanger
isoform 3 (NHE3)69,70. Coupled with the downregulation of the sodium/potassiumATPase (Na+/K+), PTH decreases the transcellular transport of sodium within the
proximal tubule, an effect that over time would tend to produce volume depletion and
hypotension49,71.
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Due to its systemic effects on the kidney, bone, and gut, PTH plays a crucial role
in the maintenance of total body calcium and phosphate homeostasis. Imbalances in
phosphate and calcium occur in the case of primary hyperparathyroidism, wherein
FIGURE 2

Figure 2: Effects of acute PTH on the proximal tubule. Acute stimulation of the
proximal tubule by PTH results in (A) decreased hydrogen secretion through downregulation of NHE3, (B) decreased phosphate reabsorption through down-regulation
of NpT2a, (C) increased gluconeogenesis, (D) increased ammoniagenesis, and (E)
decreased sodium reabsorption through down-regulation of Na+/K+-ATPase.

13

chronic elevated serum PTH causes increased serum calcium and decreased serum
phosphorus levels. Accordingly, patients with untreated primary hyperparathyroidism
display higher incidences of mineral disorders, including aortic valve calcification,
hypertension, and kidney stones72,73. Acute stimulation of the proximal tubule by PTH
results in downregulation of bicarbonate, sodium, and phosphate reabsorption, but
clinical observations suggest that the chronic effects of PTH differ from the acute effects.
Patients with primary hyperparathyroidism do not consistently display volume depletion
or metabolic acidosis74,75, which would be expected from sustained downregulation of
NHE3 and Na+/K+. Whereas many PTH responses in the proximal tubule seemingly
desensitize over time, downregulation of phosphate reabsorption persists. The studies
presented within this dissertation seek to clarify the mechanism for the chronic
downregulation of Npt2a by PTH.
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CHAPTER II
PRELIMINARY DATA

Npt2a expression in the proximal tubule

The rate of phosphate reabsorption in the proximal tubule is directly related to the
relative abundance and stability of Npt2a in the apical membrane. The expression of
Npt2a in the brush border membrane is heavily reliant on its interaction with the
scaffolding protein NHERF-1 (sodium-hydrogen exchanger regulatory factor 1). As its
name implies, NHERF-1 was originally identified for its role in the regulation of NHE3,
but has since been identified as a protein with more global function than just regulation of
sodium-hydrogen exchange45,76. Of the population of Npt2a present in the apical
membrane of the proximal tubule, approximately 35-50% is bound to NHERF-1, and this
interaction stabilizes Npt2a in the membrane and prolongs its retention there77. NHERF-1
contains two PDZ domains – a conserved motif among scaffolding proteins that is crucial
for its interaction with other proteins. Mutation analyses have shown the PDZ-1 domain
of NHERF-1 to be critical not only for NHERF1-Npt2a associations, but also for
regulated membrane expression50. As an indication of its biological importance, the
NHERF-1 PDZ domain is highly conserved across species50, and serves as a regulatory
target for several hormones, including PTH. NHERF-1 assembles a complex of proteins
involved in PTH receptor (PTHR1) signaling, including PTHR1, PLCβ, AKAP79/150,
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and actin78, and stabilizes the apical expression of those complexes through its interaction
with the cytoskeleton79. Accordingly, NHERF-1 is also required for maximal PTHresponsive inhibition of phosphate uptake80. In addition to the assembly of the PTH
receptor complex, however, NHERF-1 also augments phosphate uptake inhibition by 8Br-cAMP, PMA, and forskolin (activating PKA, PKC, and adenylyl cyclase,
respectively), indicating a role for NHERF-1 in PTH receptor signaling beyond the
assembly of the PTHR1 complex80.
PTH-stimulated endocytosis of Npt2a occurs through the phosphorylation of a
serine residue in the PDZ domain of NHERF-177, which induces the rapid dissociation of
Npt2a from NHERF-1. Maximal disassociation occurs 30 to 40 minutes following PTH
stimulation32. Whereas Npt2a undergoes rapid endocytosis in response to PTH, NHERF1 remains present in the membrane, as an important regulator for other ion transporters
and protein complexes not involved in phosphate transport32. Following endocytosis to
the endosomal compartment, Npt2a is targeted to lysosomes for degradation81,82. Reinsertion of Npt2a back into the apical membrane following removal of the PTH stimulus
requires de novo synthesis, and thus takes several hours before new Npt2a begins to
repopulate the apical membrane83.

Discrepant effects of acute versus chronic PTH
We examined through immunohistochemistry the expression of Npt2a and the αsubunit of Na+/K+ in acutely versus chronically PTH-treated Sprague-Dawley rats. To
mimic the conditions of hyperparathyroidism, the rats were administered exogenous PTH
(5 μg PTH/kg body weight) for either 6 hours (acute exposure) or 4 days (chronic
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exposure, injected once daily). In comparison to saline-treated rats, both acutely and
chronically treated rats displayed significantly decreased expression of Npt2a (Figure 3A,
next page), as opposed to the alpha subunit of the sodium pump, which showed no
significant change in expression between control and PTH-treated kidneys (Figure 3B).
In addition to studying PTH-regulated proteins in the Sprague Dawley rat kidney,
we also explored the chronic regulation of membrane proteins in a cell culture model of
the proximal tubule, the opossum kidney (OK) cell, as described in Chapter IV Methods.
OK cells were treated with either 2h PTH to mimic acute PTH, or 3d PTH (media
replaced daily) to mimic chronic PTH stimulation. Brush-border membranes (BBM) and
basolateral membranes (BLM) were isolated following PTH treatment, and protein
expression was quantified by Western blot. As shown in Figure 4A (page 19), treatment
of cells with PTH produced a rapid and significant reduction in Npt2a BBM expression,
and this effect was sustained with chronic PTH. Expression of NHE3 did not change with
acute PTH, and actually displayed a significant increase with chronic PTH. Neither
NHERF-1 (Figure 4A) nor PTH receptor (PTHR1, Figure 4B) BBM expression changed
with either acute or chronic PTH stimulation. Isolation of basolateral membranes from
PTH-treated cells showed that expression of the α-subunit of the Na+/K+-ATPase also did
not significantly change with PTH treatment (Figure 4C).

17

FIGURE 3
(B)

Npt2a

Na+/K+-ATPase α-subunit

PTH 4d

PTH 6h

Control

(A)

Figure 3: Effect of acute and chronic PTH on proximal tubule proteins. Fourmicrometer-thick sections of Sprague Dawley rat kidneys were prepared as described in
Chapter IV Methods. Rats were treated with either vehicle, 6h PTH (5 μg/kg body
weight), or 4d PTH (5 μg/kg body weight, administered daily). Expression of (A) Npt2a
and (B) the Na+/K+-ATPase α-subunit was determined by immunohistochemistry, as
described in Chapter IV Methods. Representative picture of control or PTH-treated
kidney is shown (n=3).
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FIGURE 4

Figure 4: Effect of PTH on BBM and BLM protein expression in proximal tubule
cells. (A) OK WT cells were treated with 100nM PTH(1-34) and brush-border
membranes (BBM) were isolated as described in Chapter IV Methods. Proteins were
separated by SDS-PAGE and visualized through chemiluminescence on X-ray film.
Bands for Npt2a, NHE3, and NHERF-1 were normalized as a ratio of β-actin band. * and
*** are indicative of P <0.05 and P <0.001, respectively, versus control, as determined
by one-way ANOVA (n=4). (B) Western blot showing expression of the PTHR1 in BBM
of OK cells in response to PTH (n=3). (C) Western blot of Na+/K+-ATPase α-subunit
expression in OK cell BLM in response to PTH (n=4).
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To address the potential mechanism of the chronic down-regulation of Npt2a by
PTH, we next examined the effect of PTH on the mRNA expression of both Npt2a and
NHE3. As shown in Figure 5A, NHE3 mRNA expression is unaffected by 6h PTH,
whereas Npt2a mRNA expression (Figure 5B) displayed a significant reduction at both
the 6h (acute) and 4d (chronic) time points.
FIGURE 5

Figure 5: Effect of PTH on Npt2a and NHE3 mRNA expression. OK cells were
treated for 6h or 3d with 100 nM PTH. As described in Chapter IV Methods, RT-qPCR
was performed to quantitate (A) NHE3 mRNA expression in response to PTH (n=3), or
(B) Npt2a mRNA expression in response to PTH (n=4). * is indicative of P < 0.05, as
calculated by one-way ANOVA.
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We observed no change in NHE3 BBM expression with acute PTH, and an
increase with chronic PTH. While PTH is classically known to inhibit sodium/hydrogen
exchange at the apical membrane, Yang et al. demonstrated that acute PTH induces that
downregulation not through endocytosis of the transporter but instead through the
redistribution of NHE3 to the base of the microvilli, where it is less active84. We showed
that neither acute nor chronic PTH has an effect on NHERF-1 BBM expression,
consistent with work previously demonstrated by Weinman et al.32. Previous data
reported by our lab demonstrated that acute PTH-mediated downregulation of the
expression and activity of the sodium pump desensitizes with chronic PTH85. In OK cells,
we observed a slight decrease in Na+/K+-ATPase expression after 2h PTH treatment,
although this was not significant. In rat renal cortex, we were unable to observe through
IHC a significant decrease in Na+/K+-ATPase expression with acute PTH. However,
Na+/K+-ATPase is endocytosed to sub-membrane compartments in response to PTH, and
thus the apparent stability of Na+/K+-ATPase expression with 6h and 4d PTH may not
accurately reflect the changes in distribution of the protein in response to PTH.
The results of the qPCR studies suggest distinct mechanisms of transporter
regulation by PTH in the proximal tubule. PTH acutely downregulates NHE3 through
NHE3 phosphorylation and subsequent redistribution to the base of the microvilli84,86,
and this effect appears to desensitize with chronic PTH. We observed no effect of PTH
on NHE3 mRNA expression. In contrast to PTH-mediated NHE3 regulation, PTH
induces a rapid reduction in Npt2a BBM expression through endocytosis and lysosomal
degradation of the transporter, and this suppression of Npt2a expression is sustained with
chronic PTH. Here we report preliminary evidence that Npt2a mRNA reduction is a
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potential mechanism for the acute and chronic hypophosphatemic effect of PTH. The
experiments detailed within this chapter provide support for the idea that chronic
regulation of Npt2a by PTH occurs at the mRNA level. The subsequent studies outlined
within this dissertation build upon these findings, expand our current understanding of
Npt2a regulation by PTH, and provide a basis for the further exploration and study of
mechanisms underlying homeostatic control of serum phosphate.
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CHAPTER III
HYPOTHESIS AND SPECIFIC AIMS

Overall Aim
The work detailed within this dissertation elucidates three aspects of the
mechanism by which parathyroid hormone regulates Npt2a mRNA within renal proximal
tubules. Preliminary data addressing this physiological process has shown that PTH
regulation of Npt2a is unique, in that transcript levels of Npt2a in addition to protein
expression are decreased in response to hormone stimulation. Aim 1 determines whether
PTH affects Npt2a mRNA at the transcriptional or post-transcriptional level. Aim 2
identifies the signaling pathways that contribute to PTH-mediated Npt2a mRNA
downregulation. Lastly, Aim 3 characterizes the PTH-responsive phosphoproteome of the
proximal tubule, with a focus on identifying PTH-responsive RNA-binding proteins and
elucidating their role in PTH-mediated Npt2a mRNA downregulation.

Hypothesis
PTH induces sustained suppression of Npt2a by decreasing Npt2a mRNA levels
To address this hypothesis, this work will examine three aspects of the
mechanism(s) involving PTH-mediated Npt2a mRNA downregulation.
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Specific Aim I:
Determine whether PTH affects Npt2a mRNA at the transcriptional or posttranscriptional level
Acute PTH treatment causes a host of protein expression changes in the proximal
tubule, some of which persist with chronic PTH exposure while others desensitize.
Whereas sodium/potassium pump and sodium/hydrogen exchange expression and activity
experience a transient decrease in response to PTH, suppression of Npt2a persists with
prolonged PTH. Npt2a promoter activity does not change with PTH. However, our data
suggests the likely possibility that PTH regulates Npt2a transcript levels in addition to
inducing Npt2a protein degradation. Therefore, we hypothesize that PTH decreases
Npt2a mRNA at a post-transcriptional level. We will use kidneys from transgenic
hyperparathyroid mice and opossum kidney cells to study the effects of PTH on Npt2a
mRNA expression and stability.

Specific Aim II:
Identify the second messenger pathway responsible for the PTH-mediated effect on
Npt2a mRNA
The PTH receptor is a type II G protein-coupled receptor (GPCR) capable of
coupling with several different G proteins. The PKA and PKC signaling pathways are the
two main second-messenger pathways activated upon PTH binding to the PTH receptor.
Both pathways contribute to the regulation of Npt2a at the protein level, but it is
unknown which of these pathways contributes to the PTH-mediated decrease in Npt2a
mRNA. We hypothesize that activation of the PKA pathway is required for mediating the
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PTH-induced decrease in Npt2a mRNA. We will use the opossum kidney (OK) cell
culture line to study the effects of both the PKA and PKC pathways on Npt2a mRNA
levels.
Specific Aim III:
Characterize the PTH-responsive phosphoproteome in proximal tubule cells
Based on the results of Aim 2, we determined that PTH produces Npt2a mRNA
destabilization through both PKA- and PKC-dependent mechanisms. Therefore, we aim
to characterize the PTH-responsive phosphoproteome in the OK cell, with a focus on
identifying RNA-binding proteins that are regulated by PTH. We hypothesize that PTHmediated Npt2a mRNA destabilization is dependent on upregulated expression and/or
phosphorylation of an RNA-binding protein. We will use a proteomic approach to
identify possible protein mediators of the PTH response, focusing on differential
phosphorylation of RNA-binding proteins between control and PTH-treated cells.
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CHAPTER IV

SPECIFIC AIM I: PTH DECREASES NPT2A MRNA THROUGH
POST-TRANSCRIPTIONAL MECHANISMS

Background
The story of parathyroid hormone and renal phosphate reabsorption is an old one,
and yet an incomplete one. Decades of research dating back to the 1920s detail the effects
of PTH on proximal tubular reabsorption of the filtered load of phosphate87. The process
by which PTH regulates Npt2a protein expression has been extremely well studied, and
the kinetics of the hormone response have been determined down to the minute. In the
bloodstream, circulating PTH has a half-life of approximately five minutes88, which
suggests that under normal circumstances, the effects of PTH are rapid and short-lived.
However, pathophysiological conditions such as primary hyperparathyroidism produce
sustained elevated serum PTH levels that produce prolonged effects – most notably on
serum phosphorus, calcium, and vitamin D levels. As previously discussed, the clinical
manifestations of prolonged PTH stimulation show evidence for a mechanism of chronic
down-regulation of proximal tubular phosphate reabsorption apart from the regulation of
apical membrane protein expression of Npt2a. Considering the cellular energetics of
constitutively transcribing, synthesizing, and trafficking Npt2a to the apical membrane,
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only to be immediately pulled back into the lysosomes and degraded, it is unlikely that
PTH affects Npt2a expression solely at the protein level.
Preliminary data by our lab suggest that PTH is capable of regulating Npt2a at the
mRNA level. This finding is novel, and opens the door to exploring actions of PTH on
the proximal tubule previously unconsidered. Decreased mRNA expression of a gene can
be produced by two general mechanisms: (1) decreased transcription, or (2) decreased
mRNA stability. While limited studies on the effect of PTH on either of those
mechanisms for Npt2a regulation have been performed, Npt2a has been shown to be
regulated at the transcriptional and post-transcriptional level by several other factors.

Npt2a gene expression
In discussing the potential mechanisms for regulation of Npt2a mRNA
expression, it serves to examine elements of gene structure and function that are already
known. The human Npt2a gene is present on Chromosome 5 and has been well
characterized by several laboratories89. Both the human and the mouse Npt2a genes were
initially cloned and characterized in 1996 by Hartmann et al.90 The human Npt2a gene is
approximately 14 kb long, with 13 exons and 12 introns90,91. Within the gene promoter
region are CAAT and TATA boxes that together with the sequence of exon 1 drive gene
transcription. Additionally, within both the human and murine genes, the translation
initiation site is found within exon 290.
The promoter region of the Npt2a gene has several cis-acting elements that
govern its transcription. The transcription initiation site was identified as an adenosine
residue 57 base pairs upstream of the 3’ end of the first exon (44 base pairs long), with
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the TATA box 28 bp still upstream from that91. Further upstream of the TATA box in the
5’ flanking region of the Npt2a gene, there are several cis-acting elements, including a
cAMP responsive element, as well as binding sites for the transcription factors AP-1, AP2, and Sp191. This 5’ flanking region of the NpT2 gene also contains a Vitamin D
Response Element, as well as elements responsible for kidney-specific gene
expression91,92.
Npt2a promoter function is influenced by several factors. Basal rates of Npt2a
transcription are affected by internal factors, including NHERF-1, as well as external
factors such as vitamin A, vitamin D, and thyroid hormone. Basal levels of vitamin D
appear to maintain juxtamedullary expression of Npt2a, as deficiency of vitamin D leads
to decreased Npt2a mRNA and protein expression that is restored upon administration of
vitamin D. In vitamin D-deprived rats, administration of vitamin D increases Npt2a gene
promoter activity, leading to increased Npt2a mRNA and protein expression92. However,
this is thought to be a weak effect, as increased vitamin D stimulation fails to elicit
physiological effects in phosphate reabsorption beyond baseline uptake6. Vitamin A has
also been shown to play an important role in Npt2a gene expression. Retinoic Acid
Response Elements (RAREs) were identified within the promoter of the Npt2a gene by
Masuda et al.93, who discovered that a deficiency in vitamin A induces increased renal
phosphate excretion through down-regulation of both the Npt2a and Npt2c genes.
NHERF-1, the regulatory protein important for Npt2a protein maturation and membrane
localization, has also been shown to be important for the expression of the Npt2a gene, as
demonstrated by Khundmiri et al., who showed that OK cells lacking NHERF-1
expressed less Npt2a mRNA than their WT counterparts, and that Npt2a transcript levels
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were restored upon transfection of NHERF-1-deficient cells with human NHERF-1
constructs94. Lastly, thyroid hormone has also been identified as another factor that
upregulates Npt2a gene expression by increasing its promoter activity. Ishiguro et al.95
identified thyroid hormone responsive elements (TRE) within intron 1 of the Npt2a gene,
and showed that T3 upregulates Npt2a gene expression in a renal cell-specific manner.
Conversely, there are also several factors known to downregulate Npt2a promoter
function. Elevated levels of bicarbonate/carbon dioxide independent of pH were shown
by Jehle et al.96 to decrease Npt2a promoter function, and thereby decrease protein
expression and phosphate transport. Vitamin D, in addition to activating Npt2a promoter
activity, can also indirectly decrease Npt2a gene transcription, as vitamin D also
upregulates fibroblast growth factor 23 (FGF23), a phosphaturic hormone. FGF23
activates ERK1/2 signaling in the proximal tubule, and this results in phosphorylation of
NHERF-1 with the subsequent endocytosis and degradation of Npt2a57. However, in a
classic endocrine negative feedback loop, FGF23 decreases expression of 1αhydroxylase, leading to decreased levels of 1,25-dihydroxyvitamin D and also decreased
expression of Npt2a55,62. Transgenic mice featuring overexpression of FGF23 present
with increased serum FGF23 and Klotho levels, and, notably, decreased Npt2a mRNA
expression97.

Post-transcriptional regulation of Npt2a
While several studies have demonstrated mechanisms for robust regulation of
Npt2a expression at the gene level, others also demonstrate unique mechanisms for
regulating Npt2a expression at a post-transcriptional level. Factors that have been shown
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to modulate Npt2a mRNA stability include serum phosphate levels, glucocorticoids, and
estrogen. Npt2a mRNA expression does not change in response to acute changes in
dietary phosphate, but does however change in response to chronic changes in dietary
phosphate98–100. Chronic low phosphate diets induce increased expression of Npt2a
protein and mRNA in renal proximal tubules. Low serum phosphate induced by chronic
low phosphate diets is accompanied by an increase in cytosolic calcium, and that increase
has been shown to be critical for the upregulation of Npt2a transcript expression in
response to low phosphate diets101. Tenenhouse et al.99 propose that this is due in part to
post-transcriptional changes in Npt2a mRNA stability, as the increase in Npt2a protein
expression produced by chronic low phosphate is much greater than the increase in Npt2a
mRNA expression. Later, Moz et al.3 supported this tenet when they showed that
hypophosphatemia induces increased binding of cytosolic proteins to the 3’ and 5’ UTR
of Npt2a mRNA, thus increasing stability and translation. Apart from regulation by
serum phosphate, glucocorticoids decrease both Npt2a protein and mRNA expression102–
104

, the latter due to effects independent of promoter activity. Estrogen has been shown to

downregulate Npt2a mRNA expression in a manner independent of the estrogen receptor
alpha isoform (ERα)5, potentially by decreasing transcript stability. Chronic Angiotensin
II105 and acute inflammation in response to LPS administration106 have also been shown
to post-transcriptionally modulate Npt2a expression.

Evidence for a role of PTH in the regulation of Npt2a gene expression
The vast majority of studies that have examined regulation of Npt2a by PTH have
focused on regulation at the protein level. While it has been clearly demonstrated that
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apical protein expression of Npt2a is greatly diminished in response to PTH, few studies
have examined whether regulation of the transporter also occurs at the mRNA level, and
those that have studied the effect of PTH on Npt2a mRNA expression have been limited
and inconclusive. Kilav et al.107 were unable to demonstrate an effect of elevated PTH on
Npt2a mRNA in a rat model of diet-induced hyperparathyroidism. However, the diet was
only sustained for three weeks, and thus may not have provided sufficient time to observe
changes in transcript levels. Confounding systemic effects from the diet itself may have
also counteracted any potential downregulatory actions of the elevated PTH itself. In
contrast to Kilav’s findings, three other laboratories have reported an effect of PTH on
Npt2a mRNA. Kempson et al.81 showed that acute PTH treatment in
parathyroidectomized rats decreased Npt2a mRNA expression by 30%. Independently,
Moe et al.108 demonstrated that rats with hyperparathyroidism secondary to chronic
kidney disease display a 50% reduction of levels of the Npt2a transcript. Friedlaender et
al.63 reported modest inhibitory effects of PTH on Npt2a mRNA expression in PTHinfused rats, which was augmented further when administered alongside vitamin D.
Decreased transcript levels can generally be produced by either decreased gene
promoter activity or by decreased mRNA stability, and work done by Hilfiker suggests
that the inhibitory effect of PTH on Npt2a mRNA may be due to the latter. In their
studies on the Npt2a gene promoter, Hilfiker et al.109 showed that PTH has no inhibitory
effect on Npt2a promoter function. However, they did not examine Npt2a mRNA
expression in response to PTH. While some controversy exists as to whether PTH
regulates Npt2a mRNA levels, our preliminary data show a significant inhibitory effect.
Since PTH has been shown to have no effect on Npt2a gene promoter activity, changes in
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Npt2a mRNA levels in response to PTH most likely occur at the post-transcriptional
level. Our preliminary data, as well as the aforementioned studies on Npt2a mRNA
expression in response to PTH, indicate PTH is capable of regulating Npt2a beyond the
protein level. What has not been defined is the mechanism(s) for the PTH-mediated
decrease in Npt2a mRNA. Based on our preliminary data and literature review, we
hypothesize that PTH decreases Npt2a mRNA at a post-transcriptional level. The studies
outlined in this chapter build upon our novel finding that Npt2a mRNA expression is
controlled by PTH.
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METHODS AND MATERIALS

Materials: Bovine PTH (1-34) was purchased from Bachem Biosciences Inc. (King of
Prussia, PA). Antibody against mouse Npt2a was a generous gift from Dr. Moshe Levi
(University of Colorado). Opossum Npt2a antibody was developed as described
previously110. NHERF-1 antibody was a gift from Dr. Weinman (University of
Maryland)76. HRP-conjugated β-actin antibody was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). PTH receptor antibody was purchased from Covance
(Princeton, NJ). Monoclonal antibodies against Na+, K+ ATPase 1-subunit were
purchased from Sigma-RBI (Natick, MA). Applied Biosystems PCR TaqMan PreDeveloped Assay Reagents and Ambion MirVana miRNA isolation kits were purchased
from Life Technologies (Grand Island, NY). Immunohistochemistry reagents were
purchased from Vector Laboratories (Burlingame, CA). Unless otherwise specified, all
other chemicals were purchased from Sigma-Aldrich (St. Louis, MO).

PTH-D1 mouse model: The PTH-D1 mouse is a transgenic mouse model of primary
hyperparathyroidism, wherein the mouse develops gradual hyperplasia of the parathyroid
glands due to parathyroid-specific cyclin D1 overexpression. In response to the
parathyroid hyperplasia, these mice gradually develop biochemical and histological
features of primary hyperparathyroidism, including elevated PTH, high serum calcium,
and low serum phosphorus111,112. PTH-D1 kidneys were either frozen in liquid nitrogen
for later analysis by qPCR and Western blot, or were fixed overnight in
paraformaldehyde and embedded in paraffin for analysis by immunohistochemistry.
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Kidneys from control mice of the same background strain as the PTH-D1 mice (FVB)
and similar age were used for immunohistochemical and Western blot analyses. Control
mRNA from 8-month-old FVB mice for qPCR experiments was a generous gift from Dr.
Paul Epstein, University of Louisville.

Cell culture: Studies involving time-dependent effects on Npt2a mRNA stability were
conducted using the opossum kidney (OK) cell line, a continuous renal proximal tubule
cell culture model derived from the Virginia opossum113. Importantly, the OK cell
expresses PTH-responsive proteins, including the PTH receptor (PTHR1), coupled to Gs
and Gq. Gs and Gq activate PKA and PKC, respectively, resulting in downregulation of
Npt2a expression114. OK cells were cultured in Eagle’s Modified Essential Medium
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin in a
humidified incubator at 37°C and 5% CO2. Unless otherwise noted, cells were grown to
90-95% confluence on 6-well plastic plates (Corning, Tewksbury, MA) and serumstarved overnight prior to treatment.

Immunohistochemistry: Immunohistochemical staining of PTH-D1 and control FVB
kidneys was performed for Npt2a, Na+-K+ ATPase α-subunit, NHERF-1, and the PTH
receptor. Four-µm-thick sections were shaved from PTH-D1 and FVB kidneys fixed in
paraffin blocks using a Leica RM2125RT microtome, and mounted on glass slides
(Fisher, Pittsburgh, PA). Paraffin was cleared from slides by three washes with xylene
(all washing steps were performed for five minutes unless otherwise noted). Kidneys
were rehydrated by ethanol gradient (100%, 95%, 70%) followed by two five-minute
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water incubations and a final Tween-Tris-Buffered Saline (TTBS) wash. Slides were
incubated in a low-pH citrate buffer solution (Vector Labs) for 20 minutes in a 95°C
water bath to retrieve the antigen. Following a 20-minute cooling period at room
temperature, slides were washed three times in water. Endogenous peroxidase was
quenched with 3% H2O2, followed by three more washes with water and one wash with
TTBS. Slides were incubated in 2.5% horse serum in TTBS for 30 minutes at room
temperature to block non-specific binding. Sections were then incubated overnight at 4°C
with primary antibodies against Npt2a (1:5000), Na+-K+ ATPase α-subunit (1:2000),
NHERF-1 (1:1000), or PTHR1 (1:200), diluted with 1% BSA, 0.5% Triton X-100, and
0.5% Tween-20 in water. Following primary antibody incubation, slides were washed
three times with TTBS and incubated with biotin-conjugated secondary antibodies for 30
minutes at room temperature. Slides were again washed three times with TTBS,
incubated at room temperature for 30 minutes with Vectastain ABC reagent (Vector
Labs), an avidin-biotin enzyme complex, followed by three more washes with TTBS.
Sections were incubated with 3,3’-Diaminobenzidine (DAB, prepared according to
Vector protocol) and monitored under a microscope. Following visualization of
chromatographic tubule staining, slides were quenched in water to stop the colorimetric
reaction, and counterstained with methyl green. Digital Images were obtained with a Q
Color 5 camera attached to an Olympus BX51 microscope using Image pro
software. Immunostaining was quantified with Image-Pro 6.2 software (Media
Cybernetics, Silver Spring, MD). Five visual fields of cortex per kidney section were
randomly selected and captured with a 40x objective. Positive DAB staining was defined
in a color profile by selecting a range of DAB staining intensities and the profile was
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applied to all images collected. Values for total staining area/field were obtained and
presented as sum of staining area for each group.

Brush Border Membrane (BBM) and Crude Membrane (CM) isolation: Brush-border
membranes were isolated from OK WT cells grown on 0.1 µM transwell filters using the
MgCl2 precipitation method. Following PTH or actinomycin D treatment, cells were
washed twice with ice-cold PBS and scraped into 2mL tubes with 5mM Tris 50mM
mannitol buffer pH 7.4. Cells were subjected to high-speed (20,500 rpm) homogenization
with a PowerGen 125 polytron homogenizer (Fisher Scientific) for three 30-second
intervals with an interval of 30 seconds between each stroke. Following homogenization,
MgCl2 was added to the homogenate to a final concentration of 10mM and incubated on
ice for 20 minutes with periodic vortexing. The homogenate was spun at 2000 rpm for 5
minutes at 4°C, and the pellet was discarded. The resulting supernatant was spun at
18,000 rpm for 45 minutes at 4°C to pellet brush-border membranes. The pellet was
resuspended in 5mM Tris 300mM mannitol buffer pH 7.4. For crude membrane isolation
from PTH-D1 and FVB mouse kidneys, minced kidney cortex was first homogenized in a
glass Teflon homogenizer with ten complete strokes. The homogenate was then subjected
to high-speed homogenization as described above, without MgCl2 precipitation, followed
by a low-speed and a high-speed spin.

Protein determination: Protein concentration of BBM and CM preparations was
determined using a bicinchoninic acid (BCA) protein kit (Sigma) using bovine serum
albumin (BSA) as a standard.
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Western blot analysis: Following protein estimation, equal amounts of membrane
proteins were heated in Laemmli buffer at 95°C for 5 minutes to denature proteins.
Protein samples were separated on a 10% acrylamide gel by SDS-PAGE, and then
transferred to a nitrocellulose membrane for immunodetection. Nitrocellulose blots were
incubated in TTBS containing 5% milk at room temperature for 1 hour in order to block
nonspecific binding to the membrane. Membranes were then incubated with primary
antibodies diluted in 5% milk in TTBS overnight at 4°C on a rocker. Following overnight
incubation, membranes were washed with TTBS three times for five minutes and once
for 15 minutes. Membranes were then incubated in HRP-conjugated secondary antibodies
diluted in 5% milk in TTBS for 1 hour at room temperature, followed by another round
of TTBS washing. Bands were detected by chemiluminescence (Pierce), and visualized
on X-ray film.

Isolation of total RNA: OK cells were processed to isolate total RNA according to the
manufacturer’s instructions (MirVana miRNA isolation kit, Life Technologies, Grand
Island, NY). RNA concentrations were quantified at 260 nm wavelength with 280 nm
wavelength as reference. For isolation of RNA from mice, kidney cortex from PTH-D1
mice was dissected from decapsulated kidneys and homogenized with a pestle in
MirVana lysis buffer. Once homogenized, total RNA was isolated as described above.

Quantitative real-time PCR: 1 μg of RNA was reverse-transcribed to cDNA using a BioRad MyCycler thermal cycler with the High Capacity RNA-to-cDNA Master Mix system
(Applied Biosystems, Foster City, CA) in a reaction volume of 25 μL. Reverse
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transcription was carried out at 25°C for 5 min, 42°C for 45 min, and heat inactivated at
85°C for 5 min. Resulting cDNA was diluted four-fold prior to PCR, to a final volume of
100 μL. 5 μL of diluted cDNA was PCR-amplified using FAM detection and TaqMan
Gene expression system with 50 nM Npt2a primers. 18S rRNA was used as a control
house-keeping gene reference. For OK cells, Npt2a forward primer sequence was 5’TCTGAGAGTGCTGATGTACCTAAGT-3’, and reverse primer sequence was 5’AGGTACTCATCCAACACCAGGTAT-3’. Real-time PCR was then conducted in an
Applied Biosystems 7500 Real Time PCR System with thermocycling setting of 50°C for
2 min, 95°C for 10 min, and 40 repeats of 95°C for 15 sec followed by 60°C for 1 min.
Relative quantitation was achieved by normalizing to 18S rRNA reference values, as
detected through FAM-MGB, and by calibrating to control cells using the 2-ΔΔCt method
as described in Applied Biosystems User Bulletin 2: Rev B. For mouse RNA samples, the
ΔCT value was determined using 18S and ΔΔCT values determined using the ΔCT value
from one FVB control as the calibrator for all samples (FVB and PTHD1). For OK cell
time course, the Npt2a mRNA levels were expressed relative to control (t=0) that was set
to 100 for each experiment. The average values from 4-6 independent experiments +/SEM were plotted on a semilogarithmic scale and the half-life calculated by linear
regression.

Luciferase reporter gene assays: Npt2a promoter-luciferase reporter gene constructs
(Npt2a-luc) containing -208 bp and -4700 bp were a generous gift of Heine Murer115.
Npt2a-luc or pGL3-basic and Renilla luciferase reporter (pRL-TK, Promega) plasmids
were cotransfected into OK-WT cells using Lipofectamine 2000 (Invitrogen). At 24 h
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post-transfection, firefly luciferase and Renilla luciferase activities were determined
using Dual-Glo Luciferase Assay System (Promega) according to the manufacturer's
protocol. The Luciferase:Renilla ratios were determined per well. For each independent
experiment the cells were transfected in triplicate, and the values averaged.

Statistics: Data are shown as mean ± SE. The n values represent the number of
independent experiments. Each experiment was performed in triplicate unless otherwise
indicated. P values were calculated by Student’s t-test or by one-way or two-way
ANOVA, followed by Bonferroni analysis using GraphPad Prism software. A P value
<0.05 was a priori considered statistically significant.

Ethical aspects of the proposed research: All animal studies in this dissertation were
performed in accordance with the University of Louisville IACUC. Radiation
experiments throughout this dissertation were performed under the auspices of the
University of Louisville Radiation Safety Office. We have reviewed the literature and
concluded that our proposed research does not needlessly duplicate previous studies. We
have examined every aspect of our research plan for biohazards and have made all the
appropriate arrangements to ensure that no one’s health is damaged in performing these
experiments
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RESULTS

Part 1: Effect of chronic primary hyperparathyroidism on renal tubular proteins

To examine the effect of PTH on Npt2a mRNA expression in vivo, studies were
conducted using a transgenic mouse model of chronic primary hyperparathyroidism, the
PTH-D1 mouse. This model was developed and characterized by Andrew Arnold’s
laboratory, and features parathyroid-specific cyclin D1 overexpression, leading to the
gradual development of primary hyperparathyroidism111,112. The 8-month-old PTH-D1
model of chronic hyperparathyroidism is advantageous due to the animal’s endogenous
over-production of PTH, eliminating the need for invasive thyroparathyroidectomy
surgery and administration of exogenous PTH, thus relieving stress on the animal and
mimicking more closely the human condition of primary hyperparathyroidism. Consistent
with the clinical features of primary hyperparathyroidism, these animals develop elevated
serum PTH and Ca2+ and decreased serum Pi111.
IHC using kidneys from control and PTH-D1 mice confirmed that the PTH-D1
mice display chronically reduced expression of Npt2a in the proximal tubule in
comparison to age-matched control mice (Figure 6A and 6E); the expression of the
Na+/K+-ATPase α1 subunit, PTHR1, and NHERF-1, however, did not differ (Figures 6B
– 6D) between the two animal models. Crude membranes isolated from kidney cortex of
FVB and PTH-D1 mice also showed no expression differences in the Na+/K+ α1 subunit
or NHERF-1 (Figure 6F).
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FIGURE 6

Figure 6: Proximal tubule protein expression in response to chronic PTH.
Immunohistochemical staining for (A) Npt2a, (B) Na+/K+-ATPase α1-subunit, (C)
NHERF-1, and (D) PTHR1 in control FVB and PTH-D1 mouse kidneys. (E) Quantitation
of Npt2a IHC staining from (A). (F) Crude membranes were prepared from cortex of
FVB and PTH-D1 kidneys and Western blot analyses performed for NHERF-1 and
Na+/K+ ATPase α1-subunit expression. Images shown are representative (n = 6). * is
indicative of P < 0.05, as determined by student’s t-test.
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Renal proximal tubule Npt2a expression analysis of the PTH-D1 mouse is
consistent with the biochemical characterization performed by Imanishi et al.111,
confirming the utility of this mouse model for exploring mechanisms of chronic
phosphate regulation by PTH. To address the mechanism for the chronic down-regulation
of Npt2a by PTH, Npt2a mRNA expression in control versus PTH-D1 mice was
examined. As shown in Figure 7, PTH-D1 mice express Npt2a mRNA levels
approximately 50% less than that of age-matched control mice.

FIGURE 7

Figure 7: Npt2a mRNA expression in PTH-D1 mice. RT-qPCR with mRNA isolated
from control and PTH-D1 kidneys (as described in Methods) revealed an approximate
50% decrease in Npt2a in hyperparathyroid PTH-D1 kidneys as compared to agematched control animals. * is indicative of P < 0.05.
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Part 2: Time-dependent effects of PTH on Npt2a mRNA

To further explore the effect of PTH to Npt2a mRNA levels, the opossum kidney
cell culture model, a continuous cell line derived from the Virginia opossum, was used to
study time-dependent effects of PTH on Npt2a mRNA levels. OK cells were treated with
100nM PTH (1-34) from 30 minutes up to 24 hours. RNA was isolated as described in
Methods, and reverse-transcribed into cDNA. Quantitative PCR was performed to
measure Npt2a mRNA expression. PCR showed that PTH treatment caused a very rapid
decrease in Npt2a mRNA, with an approximate 30% reduction observed after 30 minutes
of PTH, reaching statistical significance at the 1h time point (Figure 8). Npt2a mRNA
levels continued to decrease in response to PTH in a time-dependent manner, with an
ultimate reduction of approximately 75% achieved by 24h PTH. As calculated by linear
regression, the level of Npt2a mRNA fell by 50% after 2.2 hours of PTH treatment.

FIGURE 8

Figure 8: Npt2a mRNA expression in response to PTH in OK cells. RT-qPCR with
mRNA isolated from OK WT cells treated with 100nM PTH (1-34) for times indicated. *,
**, and *** are indicative of P < 0.05, 0.01, and 0.001, respectively, as calculated by oneway ANOVA.
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Part 3: Roles of transcription and translation in Npt2a mRNA stability

To compare the stability of Npt2a mRNA under basal conditions and after
treatment with PTH, OK cells were treated with actinomycin D, an inhibitor of
transcription, over the course of 12 hours. Npt2a mRNA displayed a time-dependent
decrease (Figure 9A), which achieved significance by the 4-hour time point, and an
ultimate reduction of approximately 60% was observed by the 12-hour time point. Under
conditions of halted transcription, Npt2a mRNA displayed a 50% reduction after 8.6h,
which is substantially longer than the amount of time required to achieve a 50% reduction
in Npt2a mRNA during PTH treatment. To determine if the inhibitory effect of PTH on
Npt2a mRNA expression involved transcription, OK cells were next pretreated with
actinomycin D alone for 30 minutes, followed by combined treatment with actinomycin
D and PTH. As shown in Figure 9B, the time-dependent decrease in Npt2a mRNA was
blunted, only showing a significant decrease by the 4-hour time point. Treatment of OK
cells with PTH while blocking transcription produced a curve very similar to that of
actinomycin D alone, and was significantly different from the curve produced by PTH
alone (Figure 9C). At the protein level, actinomycin D alone had little effect on brushborder membrane expression of Npt2a (Figure 9D). However, inhibiting transcription
while treating OK cells with PTH did not prevent PTH-mediated endocytosis and
degradation of Npt2a from the apical membrane, indicating that PTH-induced Npt2a
protein degradation and PTH-induced Npt2a mRNA degradation are mechanistically
independent events.
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FIGURE 9

Figure 9: Role of transcription in Npt2a mRNA regulation. RT-qPCR with mRNA
isolated from OK WT cells treated with (A) Actinomycin D (Act D, 1 µg/mL), or (B)
combined PTH and Act D (with 30min Act D pretreatment), for times indicated. *, **,
and *** are indicative of P < 0.05, 0.01, and 0.001, respectively, as calculated by oneway ANOVA. (C) Comparison of time courses with PTH alone, Act D alone, and
combined PTH + Act D treatment. * and ** are indicative of P < 0.05 and 0.01,
respectively, between both Act D alone and PTH + Act D versus control. # is indicative of
P < 0.05 for PTH + Act D versus control, as calculated by two-way ANOVA. (D) Western
blot shows Npt2a BBM expression in response to PTH alone [P], Act D alone [A], or
PTH and Act D combined [A+P]. Representative image shown (n = 3).
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Similar to the previous experiment of inhibiting transcription in the presence of
PTH, OK cells were next treated with cycloheximide, an inhibitor of translation, in the
presence or absence of PTH. As shown in Figure 10, the inhibitory effect of PTH on
Npt2a mRNA was blocked by cycloheximide treatment. Following 2h of combined PTH
and cycloheximide treatment, Npt2a mRNA expression was only reduced by
approximately 25%. This preservation of Npt2a mRNA in the presence of both
cycloheximide and PTH was maintained after 6h of combined treatment, in which Npt2a
mRNA expression was significantly higher than in cells treated with PTH for 6h.

FIGURE 10

Figure 10: Role of translation in Npt2a mRNA regulation. OK cells were treated with
cycloheximide (Chx, 1 µg/mL) in the presence or absence of PTH. Cells treated with
cycloheximide alone (Chx) or both cycloheximide and PTH (P + C) received a 30m
pretreatment with cycloheximide alone. * is indicative of P < 0.05, as calculated by oneway ANOVA.
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Part 4: Effect of PTH on Npt2a promoter activity

To confirm that the mechanism whereby PTH decreases Npt2a mRNA is posttranscriptional, luciferase reporter assays were performed to determine whether PTH has
any effect on Npt2a gene promoter activity. Luciferase reporter constructs featuring
either full-length Npt2a promoter (4700 bp) or a truncated promoter (208 bp) that
displays twice the activity as the full-length promoter were transfected into OK cells.
These cells were then treated with PTH for 8 or 24 hours, and luciferase activity was
calculated relative to Renilla as a transfection control. Reporter assays showed no effect
of PTH on Npt2a promoter function with either the full-length promoter or truncated
version (Figure 11).
FIGURE 11

Figure 11: Effect of PTH on Npt2a promoter function. OK cells were co-transfected
with Npt2a full-length (4700 bp) or truncated (208 bp) promoter luciferase constructs,
and Renilla constructs as internal control, as described in Methods. Luciferase values are
shown normalized to Renilla values.
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DISCUSSION

Here we provide evidence that PTH selectively produces a sustained reduction in
Npt2a expression at the protein and mRNA level in the renal proximal tubule. In a mouse
model of primary hyperparathyroidism, Npt2a expression remained suppressed while the
sodium pump and the PTH receptor displayed no significant changes in expression. PTH
stimulation of the proximal tubule induces the rapid endocytosis of Npt2a, followed by
lysosomal degradation of the transporter, thus requiring de novo synthesis for the
reinsertion of Npt2a back into the membrane. While PTH is a known regulator of Npt2a
protein degradation, here we show that PTH also regulates the rates of de novo synthesis
through its effects on Npt2a mRNA levels in the cell. In both hyperparathyroid models
used in this study, PTH significantly and rapidly reduced Npt2a mRNA expression
through post-transcriptional mechanisms. The Npt2a gene promoter has several cis-acting
elements in it, including cAMP response elements, introducing the possibility that PTHstimulated cAMP signaling may regulate Npt2a promoter activity. However, we observed
no effect of PTH on Npt2a promoter function, either at the 8h or 24h time point, so while
Npt2a gene promoter function is regulated by several factors, PTH is not one of them.
This observation is in accordance with previous studies published by Hilfiker et al.109,116.
The luciferase reporter assays thus support the notion that the PTH-mediated decrease in
Npt2a mRNA is a strictly post-transcriptional process.
Exploring further the mechanism behind the regulation of Npt2a mRNA by PTH,
we found that the effect of PTH on Npt2a is dependent on both transcription and
translation. We found the basal reduction of Npt2a mRNA to the 50% level required 8.6

48

hours, but PTH greatly reduced that time to just over 2 hours. Inhibiting transcription
with actinomycin D while treating cells with PTH completely blocked the ability of PTH
to destabilize the transcript. The dependence of PTH-mediated destabilization of Npt2a
mRNA on transcription suggests two possibilities – either upregulation of a miRNA or
upregulation of a protein is responsible for mediating the PTH response. Inhibiting
translation with cycloheximide while treating OK cells with PTH showed that the PTH
effect is also dependent on translation. While the rapid reduction of Npt2a mRNA is
consistent with miRNA involvement, the observation that this is a cycloheximidesensitive mechanism indicates that enhanced protein synthesis, potentially of an RNAbinding protein, is vital for this destabilization process.
While this is the first report of protein synthesis potentially leading to altered
Npt2a mRNA stability in response to PTH, previous studies have demonstrated that
Npt2a mRNA stability is regulated in response to various stimuli through differential
protein expression. In a study where hypophosphatemia increases Npt2a mRNA levels,
Moz et al.3 showed that a low phosphate diet in rats induces post-transcriptional
stabilization of Npt2a mRNA. In their model of hypophosphatemia, a low phosphate diet
induced increased production of renal cytosolic proteins, and that these proteins had a
protective effect on the Npt2a mRNA by binding to both the 5’ untranslated region
(UTR) and 3’ UTR. Their work indicates that there is a cis-acting instability element in
the protein-binding region of the 3’ UTR of Npt2a mRNA3,117, and that cytosolic proteins
produced in response to hypophosphatemia bind to this region and stabilize the transcript.
This influence of serum phosphate levels on Npt2a mRNA stability was also observed in
another study of a distal tubule-specific Klotho knockout mouse. This knockout mouse
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displays increased protein expression of Npt2a in the proximal tubule as a result of the
Klotho deletion, and yet decreased levels of the Npt2a transcript, perhaps in response to
the accompanying hyperphosphatemia56. Glucocorticoids, known downregulators of
sodium-phosphate cotransport in the proximal tubule, have been shown to reduce both
Npt2a protein and mRNA expression. Dexamethasone, a synthetic glucocorticoid,
decreases Npt2a mRNA and protein abundance in a manner that is also dependent on
both transcription and translation102. This study in conjunction with ours suggests the
possibility that the characteristics of the specific proteins interacting with the 3’ UTR of
Npt2a mRNA determine the fate of the transcript.
Combined, these studies support the notion that the changes in Npt2a mRNA
stability evoked by PTH are due to increased protein synthesis, particularly increased
expression of RNA-binding proteins. This mechanism of post-transcriptional regulation
of Npt2a by PTH is potentially unique to Npt2a alone, as we observed no effect of
chronic PTH on the expression of other PTH targets, including the sodium-potassium
pump and NHE3. In the studies described in this chapter, we have demonstrated that PTH
induces rapid destabilization of Npt2a mRNA, and that this effect is dependent on
transcription and translation. Based on these findings, we propose that PTH upregulates
the expression of an RNA binding protein that enhances Npt2a mRNA degradation.
Further studies are required to validate this hypothesis.
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CONCLUSION

Npt2a undergoes downregulation both at the protein level and the mRNA level in
response to PTH through distinct mechanisms. PTH induces rapid destabilization of
Npt2a mRNA through post-transcriptional mechanisms dependent on the upregulation of
an as-yet-unidentified protein.
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CHAPTER V

SPECIFIC AIM II: PKA AND PKC CONTRIBUTE TO PTH-MEDIATED
NPT2A MRNA DESTABILIZATION

The PTH receptor signaling complex

In Chapter IV, we established that PTH induces rapid destabilization of Npt2a
mRNA in the proximal tubule, and that this destabilization is sustained with chronic
PTH. Exploring further the mechanism of PTH-induced Npt2a mRNA destabilization, the
goal of the present chapter is to elucidate the signaling events that mediate this response.
PTH signaling in the proximal tubule is elicited through its interaction with the PTH
receptor type I (PTHR1). The PTH receptor is a member of the G protein-coupled
receptor (GPCR) family, with seven transmembrane domains, an extracellular amino
terminus, and an intracellular carboxyl terminus. The amino acid sequence of the PTH
receptor is conserved across species, with PTHR1 cloned from rat osteoblasts displaying
78% conservation to the opossum kidney PTHR1, indicating an important systemic role
for the receptor118. PTH receptor expression has been identified in a wide array of tissues,
including the uterus, gut ovaries, and liver, although expression of the PTHR1 in these
tissues is thought to be more important for paracrine/autocrine signaling by the PTH
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related peptide PTHrP, which also couples to the PTHR1119. The highest expression of
the PTHR1 within the body is found in the bone and kidney. Within the kidney, PTH
receptors have been found both in the proximal and distal tubules, as well as the
collecting duct120,121.
PTH receptors in the proximal tubule are expressed in both the apical and
basolateral membranes122. The PTH receptor is a member of the class II GPCR family,
and possesses the ability to activate several intracellular signaling pathways. It has been
shown to couple to several G proteins, including Gs and Gq, leading to the subsequent
activation of the cAMP/PKA and PLC/PKC pathways, respectively4. These
characteristics of ligand-receptor signaling are preserved in cell culture models of the
proximal tubule, including opossum kidney cells, where stimulation of the PTHR1 by
PTH produces activation of two major signaling pathways: (1) the Gαs/adenylyl
cyclase/cAMP/PKA pathway, and (2) the Gαq/11/PLC/IP3/Ca2+/PKC pathway123.
The signaling pathways activated by PTH are complex and cell-specific, and
influence more than just renal phosphate transport. Although the PKA and PKC pathways
are the primary pathways activated in the proximal tubule, PTH receptors throughout the
body differ in their structural requirements for signaling pathway activation, particularly
when it comes to phospholipase activation. Proximal tubular PTH receptors, for example,
are capable of activating different phospholipases from the ones activated by distal tubule
PTH receptors120. PTH receptors even within the same cell may differ in their G proteincoupling capacities based on their distribution in the apical versus basolateral membrane.
Early studies suggested that the PTH receptor in the proximal tubule coupled to distinct G
proteins on the apical and basolateral membranes, with apical PTH1Rs thought to
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activate PKC exclusively, whereas basolateral PTH1Rs activated both PKA and PKC124.
However, Npt2a-GST pull-down experiments by Khundmiri et al.125 showed that Npt2a
in the BBM of OK cells associates with AKAP79, PKA (both the catalytic and regulatory
subunits), and the PTH receptor, and that AKAP-mediated activation of PKA was critical
for downregulation of phosphate transport by PTH. While the aforementioned studies
provide conflicting evidence for specific G protein coupling dependent on receptor
localization, they nonetheless confirm the role of both Gs and Gq in mediating PTH
signaling within the proximal tubule.
Although the predominant signaling pathways activated by PTH include the
cAMP/PKA and PLC/PKC pathways118, there are a number of other pathways that PTH
has also been shown to activate, and these also appear to be tissue-specific. These include
phospholipase A2 in osteoblasts and proximal tubules126, phospholipase D in distal
tubules120, and the mitogen-activated protein kinase (MAPK) pathway in OK cells127. In
addition to activating PKA, cAMP also activates another category of proteins known as
exchange proteins directly activated by cAMP (Epac), which are guanine nucleotide
exchange factors for the Ras GTPase family of proteins128. Epac1 and Epac2 are both
expressed in the brush border of the proximal tubule129, and are known regulators of
several proximal tubule proteins, including NHE3, aquaporin-2, and the H+/K+-ATPase.
No evidence currently exists for a role of Epac in regulating phosphate transport128. PTH
signaling decreases Na+/K+-ATPase activity and expression via extracellular signalregulated kinase (ERK)-mediated activation of PKC- and PLA2-dependent pathways49,71.
Of the pathways activated by PTH in the proximal tubule, however, PKA and PKC
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remain the most influential in mediating downstream phosphaturic effects of PTH
signaling, and in that regard are the most highly studied.

PTH-induced PKA signaling
The PTHR1 is a potent stimulator of cAMP generation and PKA activity through
its association with the G protein Gαs. As shown in Figure 12, when activated by ligandreceptor interaction, Gαs activates the closely associated adenylyl cyclase (AC), an
enzyme that rapidly catalyzes the formation of cyclic AMP (cAMP) from ATP. Within
the AC family of proteins, nine isoforms have been identified, and the effects of those
isoforms are dependent on “signalosomes” recruited by each specific isoform130. As
studied in the rat nephron, AC isoforms II, III, VI, VII, and IX are expressed in the
proximal tubule, with II, III, and IX confirmed through IHC to be expressed only in the
apical membrane (IHC data unavailable for VI and VII)131. NHERF-1 has also been
found to be important not only in the formation of the apical membrane signalosomes,
but also for modulating the amount of cAMP generated in response to PTH stimulation,
and its presence is mandatory for cAMP inhibition of NHE350,132.
Within 10 seconds of receptor binding, PTH induces a significant accumulation of
cAMP133, which in turn activates protein kinase A (PKA) by binding to the regulatory
subunits, causing dissociation from and activation of the PKA catalytic subunits, thus
resulting in the phosphorylation of downstream targets. The cAMP signal is typically
terminated through the actions of phosphodiesterases (PDEs) that hydrolyze cAMP to
form 5’ AMP. In the case of PTH signaling, PTH also rapidly increases PDE activity in a
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dose-dependent and PKA-dependent manner, providing a negative-feedback mechanism
for the termination of PTH-induced cAMP signaling134.
The dynamics of PTH signaling vary during acute versus sustained signaling. AC
is a membrane-bound protein, and the cAMP produced by it is thus produced at the cell
membrane. However, this site of cAMP generation is short-lived, as the PTHR1
undergoes endocytosis shortly after stimulation by PTH. This series of events was
originally thought to terminate receptor signaling, as association of β-arrestins with the
internalized receptor would desensitize downstream signaling. However, more recent
studies have demonstrated that, following endocytosis of the receptor, cAMP generation
is sustained. Whereas the previous dogma held that cAMP accumulation occurred only at
the cell membrane, studies by Ferrandon et al.133 challenge this notion, when they showed
that PTH(1-34) was endocytosed to early endosomal compartments, where it not only
remained associated with the PTHR1, Gαs, and AC, but continued to produce cAMP over
a period of 20 minutes. In this manner PTH evokes sustained signal generation in the
proximal tubule, even after removal of the original stimulus.

PTH-induced PKC signaling
While the PTHR1 is well known to activate cAMP-dependent pathways by
coupling to Gs, the receptor also couples to Gq and is thus a potent stimulator of
phospholipase C (PLC)-dependent signaling. Following the activation of PLC by Gq,
PLC cleaves membrane phospholipids such as phosphatidylcholine and
phosphatidylinositol 4,5-bisphosphate (PIP2), producing the two signaling molecules
inositol triphosphate (IP3) and diacylglycerol (DAG). Downstream activation of PKC
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occurs through two processes, as shown in Figure 12. DAG directly binds to and activates
PKC, whereas IP3 binds to ligand-gated calcium channels in the membrane of the
endoplasmic reticulum. The subsequent rise in intracellular [Ca2+] produces activation of
PKC in cooperation with DAG. In OK cells, PKC is maximally stimulated 60-90 seconds
following activation of the PTHR1 by PTH32. In addition to this PLC-mediated

FIGURE 12

Figure 12: PTH-receptor binding and intracellular signaling in the proximal tubule.
Binding of the ligand to the receptor increases the affinity of the intracellular beta-gamma
binding region of the C-terminal region of the PTH receptor for G proteins, resulting in
their subsequent activation and initiation of downstream signaling cascades. Gαs activates
adenylyl cyclase (AC), which increases intracellular [cAMP], resulting in activation of
Epac and PKA. Gq activates phospholipase C (PLC), forming diacylglycerol (DAG) and
inositol triphosphate (IP3). DAG directly activates PKC, whereas IP3 indirectly activates
PKC by releasing Ca2+ from the ER.
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activation of PKC, the PTHR1s expressed in human, mouse, and opossum kidneys are
also capable of activating PKC through PLC-independent mechanisms135.
PTH-induced signaling is heavily dependent on the interaction of the PTHR1 with
accessory proteins. NHERF-1, required not only for apical membrane localization for
Npt2a, is also crucial for the regulation of PTH receptor signaling and second messenger
generation. In OKH cells, a clonal cell line of the OK WT cell that is deficient in
NHERF-1, PTH produces robust levels of cAMP, but fails to stimulate phospholipase C
and does not inhibit phosphate transport80. In cells that express PTHR1-NHERF-2
complexes, stimulation by PTH potently activates PLC signaling while inhibiting AC
through the simultaneous activation of inhibitory Gi/o proteins136. PTH is thus capable of
producing tissue-specific effects in accordance with the specific receptor-protein
interactions present within the tissue membrane.

PTHR1 endocytosis and desensitization
The cessation of GPCR signaling is generally dependent on removal of the
stimulus and receptor desensitization through endocytosis of the receptor from the plasma
membrane. GPCR desensitization is a process that normally requires receptor
phosphorylation and/or ubiquitination, promoting the association of β-arrestins that stop
receptor signaling. Resensitization thus usually requires a process of dephosphorylation
and removal of β-arrestin binding. In response to PTH stimulation, the PTHR1 carboxyterminus becomes phosphorylated, promoting β-arrestin2 binding and receptor
desensitization, followed by endocytosis to an internal compartment137. PTH induces a
transient polyubiquitination of the PTHR1 by promoting coupled ubiquitination followed
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by deubiquitination through the rapid upregulation of the deubiquitinating enzyme
USP2138. Following receptor endocytosis and desensitization, GPCRs usually re-sensitize
and recycle back to the plasma membrane, which for the PTHR1 occurs within 2h after
PTH stimulation138. The PTHR1 is unique amongst GPCRs in that it does not require
dephosphorylation or dissociation from β-arrestin in order to recycle back to the plasma
membrane139.
NHERF-1 association with the PTHR1 helps to prolong the expression of the
PTHR1 in the plasma membrane and helps sustain PTHR1 signaling. Wang et al. found
that NHERF-1 was crucial for preventing β-arrestin2 from interacting with PTHR1, as
well as for maintaining the association of the PTHR1 with Gαs137. The presence of
NHERF-1 in the apical and basolateral membranes also protects against receptor
desensitization by prolonging the retention of the PTHR1 in the plasma membrane140.
The Golgi apparatus also appears to play an important role in PTHR1 recycling, as
internalized PTHR1 colocalizes with the Golgi, and disrupting the Golgi impairs PTHR1
recycling141. In addition to its association with the Golgi, the PTHR1 has also been shown
to traffic in and out of the nucleus, although the physiological function of this trafficking
pattern is currently unknown142.

Pathways involved in Npt2a protein downregulation
The studies examining the relative contributions of the signaling pathways to the
regulation of Npt2a by PTH have been inconclusive at best. Activation of both the PKA
and PKC pathways has been shown to downregulate expression of Npt2a at the apical
membrane in proximal tubule cells77,143. Several studies using cell-based and animal-
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based models have demonstrated that the two signaling pathways both contribute to PTHmediated downregulation of Npt2a protein expression29,80,123,144,145, and the relative
contribution of each pathway is still under debate.
Several studies support a principal role for PKA signaling over PKC signaling in
the sustained downregulation of Npt2a by PTH. In mice that lack adenylyl cyclase
isoform 6 (AC6), PTH-induced endocytosis and subsequent lysosomal degradation of
Npt2a is absent146. Through the use of PTH analogues with selective signaling properties,
Nagai et al. showed that the acute down-regulation of phosphate transport in response to
PTH involves primarily the cAMP/PKA pathway123. Genetic studies in Npt2c KO mice
expressing WT or PLC-signaling-deficient PTHR1 showed that the hypophosphatemic
response to PTH in PLC-signaling-deficient Npt2c KO mice was only slightly impaired,
suggesting that chronic downregulation of Npt2a by PTH is primarily reliant on non-PLC
signaling pathways51. Support for this conclusion is seen in patients with type Ia or type
Ib pseudo-hypoparathyroidism, wherein a mutation in renal proximal tubule Gαs results
in proximal tubule-specific PTH-resistance, resulting in diminished phosphate excretion
and hyperphosphatemia147,148. This clinical picture implicates a preeminent role for PKA
in mediating downregulation of sodium-phosphate cotransport by PTH, as PLC/PKC
pathway signaling, which is presumably unaffected by the mutation, cannot compensate
for the loss of cAMP/PKA signaling.
Although several studies have implicated PKA as the primary mediator of the
PTH phosphaturic response, other studies highlight the importance of PKC signaling over
PKA signaling. Whereas Nagai et al.123 used PTH analogues to demonstrate a dominant
role for PKA signaling, Carpenter et al.149 showed preservation of the phosphaturic
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effects of PTH in the absence of cAMP generation, through the use of PTH analogues
with Gq-specific-activating properties. In mouse renal proximal tubule cells, inhibition of
PKC completely blunted the inhibitory effect of PTH on phosphate transport, while the
phosphaturic effect was unaffected by inhibiting PKA58. These studies by Cunningham et
al. suggest that the inhibitory effect of cAMP on phosphate transport is reliant on
downstream PKC activation, which would partially explain the phosphaturic effects of
PKA, but does not address the mechanism for PTH-resistant hypophosphatemia in
patients with pseudohypoparathyroidism. The differences between these studies may
highlight species discrepancies in the contribution of PTH-stimulated signaling pathways
to the regulation of phosphate transport by PTH.
PTH also activates several other signaling pathways in proximal tubule, but their
roles, both as independent contributors to Npt2a regulation as well as adjunctive to PKA
and PKC, in the regulation of Npt2a are not well understood. For instance, FGF23,
another major phosphaturic factor, decreases both Npt2a protein and mRNA abundance
through MAPK-dependent-signaling in the proximal tubule150. Although the MAPK
pathway is critical for FGF23-induced hypophosphatemia, which is independent of PKA
and PKC activation, the role of MAPK in PTH- and dopamine-mediated inhibition of
phosphate transport is unclear58. PI3 kinase and phospholipase A2 are additional
signaling pathways known to be activated by PTH, but their role in regulating phosphate
transport has not been thoroughly investigated. To date, the cAMP/PKA and PLC/PKC
pathways are known to be the most influential on phosphate transport.
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Modification of receptor coupling and signaling through PTH fragments
PTH is a peptide hormone, which in the mature, secreted form is 84 amino acids
in length. The first 34 amino acids (1-34) are the biologically active portion of the
hormone, responsible for full receptor coupling and subsequent G protein recruitment and
activation (see Figure 12)135. Deletion of select amino acids within the peptide hormone
results in an incomplete coupling of the ligand to the receptor, and a subsequent
incomplete activation of downstream signaling pathways. Thus, modification of the
amino acid composition of PTH yields analogues with selective PKA- or PKC-activating
properties. Within this chapter, the analogues PTH(1-31) and PTH(3-34) are used to
preferentially activate the PKA and PKC signaling pathways in order to better define
their contribution to PTH regulation of phosphate transport.
PTH(1-31) has been suggested as a relatively cAMP-selective PTHR1 agonist that
is deficient for both PLC-dependent and –independent PKC signaling135. Treatment of
proximal tubular cells with PTH(1-34) and PTH(1-31) produces a similar rise in cAMP,
indicating that the carboxy-terminal deletion of residues (32-34) does not interfere with
Gs activation135. PTH analogues truncated at the C-terminus further than the 31st residue,
however, fail to stimulate cAMP accumulation120. In contrast to Gs stimulation, the Cterminus (residues 32-34) was found to be critical for Gq signaling, as demonstrated by
Jouishomme et al., who showed that the PTH(29-32) fragment is the smallest hormone
fragment capable of stimulating PKC, and that the His32 residue is critical for this
stimulation to occur151. Loss of the His32 residue thus prevents PTH from activating
PKC. This property of His32-receptor coupling prevents PTH(1-31) from activating
PKC, while preserving full adenylyl cyclase-stimulating capabilities.
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Truncating PTH at the amino terminus by two amino acids yields the PTH
fragment PTH(3-34). Whereas the carboxyl terminus is crucial for activation of PKC, the
amino terminus is likewise crucial for the activation of PKA. PTH(3-34), devoid of the
amino terminal residues necessary for Gs activation, selectively activates PKC through
non-PLC-dependent mechanisms152, albeit less effectively than the full-length analogue,
and notably does not activate PKA135. Whereas stimulation of the proximal tubule by
PTH(1-31) fails to result in an increase of intracellular calcium, stimulation with PTH(334) results in a partial increase, indicating a selective role for PTH(3-34) in the activation
of PKC120. In the experiments outlined in this chapter, human PTH(1-31) is used as a
selective PKA-activating agent, whereas bovine PTH(3-34) is used as a selective PKCactivating agent.

PTH signaling and Npt2a mRNA regulation
The signaling studies of PTH-mediated downregulation of Npt2a expression have
focused solely on the secondary messenger pathways that lead to protein endocytosis and
degradation. The PTHR1 has been shown to undergo resensitization and recycling back
to the plasma membrane, and the results from Specific Aim I demonstrated that PTHR1
expression remained unchanged with chronic PTH stimulation. While no one has
examined signaling events that lead to Npt2a mRNA destabilization, given the dynamics
of PTHR1 signaling and the time frame with which those signals cease, we expect there
to be some pathway conservation between chronic protein regulation and chronic mRNA
regulation by PTH. Based on our results from Specific Aim I, we are proposing that the
mechanism of PTH-mediated Npt2a mRNA destabilization involves upregulation of an

63

RNA binding protein. Studies in bone examining PTH-responsive induction of gene
expression showed that PTH induces rapid upregulation of gene expression through the
cAMP-PKA pathway153. Given the evidence for downregulation of Npt2a protein
expression by PTH, and the sustained cAMP signaling generated by prolonged PTHR1
stimulation, we hypothesize that PKA is the primary mediator of PTH-induced Npt2a
mRNA destabilization. We will study PTH-related signaling events and their contribution
to PTH-mediated Npt2a mRNA destabilization using the opossum kidney cell line, as
previously established in Chapter IV, as a model of PTH-sensitive phosphate transport.
We also previously established in Chapter IV a time course of PTH-mediated decrease in
Npt2a mRNA that showed a rapid decrease in mRNA levels within 2h of PTH, achieving
a plateau after approximately 8h of PTH stimulation. For the purposes of these
experiments, we have defined acute PTH treatment as 30m to 2h, and chronic PTH as 6h
and 8h. We have therefore chosen to study the effects on the PKA and PKC signaling
pathways for times varying from 30m to 8h. We will use a three-pronged approach to
elucidate the signaling mechanisms in PTH-mediated Npt2a mRNA destabilization. First,
we will use PTH analogues that are selective for PKA or PKC activation. Second, we will
use pharmacologic agents to directly activate either PKA or PKC. Lastly, we will inhibit
PKA or PKC activation under conditions of PTH stimulation.
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METHODS AND MATERIALS

Materials: Bovine PTH(1-34), human PTH(1-31), and bovine PTH(3-34) were purchased
from Bachem Biosciences Inc. (Kind of Prussia, PA). Phorbol myristate acetate, 8-pCPT2′-O-Me-cAMP, and chlorpromazine were purchased from Sigma-Aldrich (St. Louis,
MO). 8-bromo-cAMP, PKC inhibitor peptide, and H-89 were purchased from
Calbiochem (La Jolla, CA). Applied Biosystems PCR TaqMan Pre-Developed Assay
Reagents and Ambion MirVana miRNA isolation kits and were purchased from Life
Technologies (Grand Island, NY). PKA and PKC activity assay kits were purchased from
EMD Millipore (Billerica, MA). ATP[32P] was purchased from Perkin Elmer (Waltham,
MA). Unless otherwise specified, all other chemicals were purchased from SigmaAldrich (St. Louis, MO).

Cell culture: Studies involving time-dependent effects on Npt2a mRNA stability were
conducted using the Opossum Kidney (OK) cell line. OK cells were cultured exactly as
previously described in Chapter IV. Unless otherwise noted, cells were grown to 90-95%
confluence on 6-well plastic plates (Corning, Tewksbury, MA) and serum-starved
overnight prior to treatment.

Protein determination: Protein concentration of OK cell nuclear-free lysates was
determined using a bicinchoninic acid (BCA) protein kit (Sigma) using bovine serum
albumin (BSA) as a standard.
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Isolate of total RNA: RNA isolation was performed exactly as previously described in
Chapter IV.

Quantitative real-time PCR: Reverse transcription and qPCR were performed exactly as
previously described in Chapter IV.

Radioactivity assays: All steps were performed on ice unless otherwise indicated.
Radioactivity assays for measurement of PKA and PKC activities were performed
according to manufacturer’s protocol. Briefly, OK cells were treated with PTH analogues
and/or PKA or PKC inhibitors as described in Results for times indicated. Cells were
washed twice with ice-cold PBS, and lysed in buffer consisting of 5mM Tris-HCl 50mM
mannitol, pH 7.4, and protease and phosphatase inhibitors. Cells were homogenized by
15 passes through a 26 gauge needle. Nuclear-free lysates were prepared by centrifuging
lysates at 750*g for 5 minutes, and discarding the pellet. 10 μL of cell lysate per
condition was incubated in a microcentrifuge tube containing 40 μL of the reaction
reagent mix (prepared according to manufacturer’s protocol) and 10 μL of the [γ-32P]ATP
mixture. The kinase reaction took place in a 30°C water bath with shaking for 10
minutes. The reaction was stopped by removing 25 μL of the reaction mixture and slowly
pipetting the aliquot onto phosphocellulose paper. Papers were washed three times with
0.75% phosphoric acid, followed by one five-minute wash with acetone. Papers were
allowed to dry before being added to scintillation vials containing 3 mL of Econo-safe
scintillation cocktail (RPI, Mount Prospect, IL). CPMs were determined using a Tri-Carb
2100TR liquid scintillation counter (Perkin Elmer, Waltham, MA). CPM of negative
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control samples containing no enzyme were used as background control. Specific
Radioactivity (S.R.) was calculated by measuring the CPM of 10 μL of the [32P]ATP
solution, and dividing that value by 5 nmoles ATP to yield units of CPM/nmole ATP.
This value was converted to CPM/pmole ATP by dividing the S.R. by 1000. PKA and
PKC activities were calculated by subtracting the background CPM (“B”) from each
sample (“S”), and calculating as follows:

[𝑆−𝐵]𝑥 2.4
𝑆.𝑅.𝑥 10𝑚𝑖𝑛

= pmole phosphate incorporated into substrate peptide/min

This value was further divided by the amount of protein loaded per sample. Each
experiment was comprised of two individual samples per condition. Within each
experiment, the data was normalized to the average of the controls, and reported as %
change from control.

Statistics: Data are shown as mean ± SE. The n values represent the number of
independent experiments. P values were calculated by Student’s t-test or by one- or twoway ANOVA, followed by Bonferroni analysis using GraphPad Prism software. A P
value <0.05 was a priori considered statistically significant.
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RESULTS

Part 1: Effects of PTH analogues on Npt2a mRNA expression
To examine the relative contribution of the PKA and PKC signaling pathways
toward PTH-mediated Npt2a mRNA destabilization, OK WT cells were treated with PTH
analogues that relatively selectively activate specific signaling pathways. OK cells were
treated with 100nM PTH(1-31) to selectively activate PKA, or 1μM PTH(3-34) to
selectively activate PKC, for up to 8h. The concentration used for PTH(1-31) was
determined according to concentrations published in previous studies135, while the
optimal concentration for PTH(3-34) was determined by performing dose response
curves of stimulated PKA activity and selecting the concentration at which PKA activity
showed the least increase. PKA and PKC activity assays were performed to confirm the
selective pathway-activating properties of each analogue. As shown in Figure 13C,
PTH(1-34) produced a 40% increase in PKA activity within 15m of treatment, which fell
to a plateau of about 20% above baseline by the 2h and 6h time points. PTH(1-31)
produced a 20% increase in PKA activity within 15m that was sustained after 2h of
treatment. PTH(3-34) also increased PKA activation by less than 20% at 15m, but this
effect was transient, decreasing to less than control levels with 6h treatment. Looking at
PKC activation by the PTH analogues, PTH(1-34) potently stimulated PKC activity by
approximately 50% at both the 15m and 2h time points, and increased further still to
200% by 6h (Figure 13D). PTH(3-34) produced a modest 20% increase in PKC activity
that was sustained after 6 hours of treatment. PTH(1-31) acute treatment induced a
similar increase in PKC activity, but this effect was transient, falling to baseline by 2h.
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FIGURE 13

Figure 13: Effect of pathwayspecific PTH analogues on Npt2a
mRNA. RT-qPCR with RNA
isolated from OK WT cells treated
with either (A) 100nM PTH(1-31)
(n=5), or (B) 1μM PTH(3-34) (n=6).
*** is indicative of P < 0.001 versus
control. (C) PKA activity and (D)
PKC activity stimulated by the PTH
analogues (n=4). * is indicative of P
< 0.05 as calculated by two-way
ANOVA. (E) Comparison of the
relative contribution of the PTH
analogues to Npt2a mRNA degradation. * is indicative of P < 0.05, comparing (1-34) to
both (1-31) and (3-34) at times indicated. # is indicative of P < 0.05, comparing (1-34) to
(1-31) at time point indicated, as calculated by two-way ANOVA.
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Statistical analysis by two-way ANOVA of PKA and PKC activation by the analogues
revealed that only PTH(1-34) produced a statistically significant increase in PKC activity
after 6h of treatment, and thus further experiments will be necessary to better differentiate
between the kinase-activating properties of each analogue. While these analogues were
not as specific in activating PKA or PKC as had been previously described, and although
both analogues failed to stimulate each kinase as strongly as PTH(1-34), we nonetheless
established that PTH(1-31) preferentially activates PKA whereas PTH(3-34)
preferentially activates PKC.
With the kinase activation properties of the analogues defined, we next
determined the effect of the analogues on Npt2a mRNA expression. Over the course of 8
hours, treatment with both PTH(1-31) and PTH(3-34) produced a time-dependent
decrease in Npt2a mRNA levels, (Figures 13A and 13B), with an approximate 45-50%
reduction from control levels achieved after 8h treatment with either analogue. Whereas
treatment with PTH(3-34) produced no significant effect on Npt2a mRNA until the 6h
time point, PTH(1-31) significantly decreased Npt2a levels within 2h of treatment. As
shown in Figure 13E, both PTH(1-31) and PTH(3-34) decreased Npt2a mRNA to a
significantly less degree when compared to that induced by PTH(1-34).

Part 2: Effects of direct activation of PKA vs PKC on Npt2a mRNA expression
To further define the contribution of the PKA and PKC signaling pathways to the
PTH-mediated effect on Npt2a mRNA expression, OK WT cells were next treated with
direct activators of the respective signaling pathways. To directly activate PKA, OK cells
were treated with 10 µM 8-bromo-cAMP (8-Br), a cell-permeable cAMP analogue that is
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resistant to degradation by phosphodiesterases. Selective Epac activation was achieved
by treating OK cells with 8-CPT-2Me-cAMP (10 μM), a cAMP analogue that retains
Epac- but not PKA-binding properties154. To directly activate PKC, OK cells were treated
with 100nM phorbol myristate acetate (PMA), a diacylglycerol mimetic. Over the course
of 8 hours, treatment with 8-Br produced a time-dependent decrease in Npt2a mRNA

FIGURE 14

Figure 14: Direct activation of signaling pathways. RT-qPCR was performed with
RNA isolated from OK WT cells (as described in Methods) treated with either (A) 10µM
8-Br-cAMP, (B) 100nM PMA, or (C) 10µM 8-CPT-2Me-cAMP, for times indicated. (A)
** and *** are indicative of P < 0.01 and 0.001, respectively, versus control, as
determined by one-way ANOVA (n = 6). (D) * and *** are indicative of P < 0.05 and
0.001, respectively, for PMA versus 8-Br, and +++ is indicative of P < 0.001 for 8-CPT
versus 8-Br, as determined by two-way ANOVA (n=6).
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levels, comparable to that achieved with PTH alone, with an approximate 55% reduction
from control levels achieved after 8h treatment with 8-Br (Figure 14A). Treatment with
PMA for up to 8h, however, failed to produce a statistically significant effect (Figure
14B). Treatment of OK cells with 10 μM 8-CPT-2Me-cAMP also resulted in no effect on
Npt2a mRNA expression (Figure 14C). In comparing the effects of selective PKA, PKC,
and Epac activation on Npt2a mRNA expression (Figure 14D), the data strongly suggest
a preeminent role for PKA action mediating the effect of PTH on Npt2a mRNA.

Part 3: Effects of select pathway inhibition on PTH-mediated Npt2a mRNA
destabilization
To support the results of the PTH analogues and direct activation studies, and to
assess the ability of PTH to affect Npt2a mRNA levels during the inhibition of the either
the PKA or PKC signaling pathways, we next treated OK cells with either an inhibitor of
PKA, H-89, or an inhibitor of PKC, PKC inhibitory peptide (PKCi), in the presence and
absence of PTH(1-34), over the course of 6h. Cells were pretreated with inhibitor alone
for 30m prior to combined PTH-inhibitor treatment for each time point, for a total
treatment time of 6.5h. To confirm the effectiveness of H-89 and PKCi as inhibitors, we
performed assays at 15m (with 30m pre-treatment) to determine the relative activity of
the kinases under the conditions aforementioned. As expected, PTH increased both PKA
and PKC activity (Figures 15C and 15D). H-89 alone resulted in a 35% reduction in basal
PKA activity, and completely prevented the activation of PKA by PTH. Inhibiting PKC
had no effect on PKA activity, but surprisingly also blunted the ability of PTH to activate
PKA. Perhaps even more surprising, H-89 also appeared to inhibit basal PKC activity,
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FIGURE 15

Figure 15: Effect of PTH on Npt2a mRNA during selective pathway inhibition. (A)
and (B) RT-qPCR with RNA isolated from OK WT cells was performed as described in
Methods. Cells were treated with (A) H-89 alone or combined PTH and H-89, or (B)
PKCi alone or combined PTH and PKCi, for times indicated. All conditions (except
control) received a 30m pre-treatment of (A) H-89 or (B) PKCi alone. *, **, and *** are
indicative of P < 0.05, 0.01, and 0.001, respectively, within time points indicated, as
determined by two-way ANOVA (n=4). (C) PKA and (D) PKC activity assays were
performed as described in Methods. Treatments shown were performed for 15m, with a
30m inhibitor pretreatment in conditions where inhibitors were present. * and *** are
indicative of P < 0.05 and 0.001, respectively, versus control, and +++ is indicative of P
< 0.001 versus PTH, as determined by one-way ANOVA (n = 6).
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whereas PKCi failed to inhibit either basal PKC activity or PTH-induced PKC activation.
While we were unable to achieve suppression of PKC activation in the presence of the
PKC inhibitor peptide following 15m PTH treatment, previous experiments showed that
PTH-stimulated PKC activity continues to increase over a 6h period. Additionally, while
we observed an approximate 15% increase in PTH-stimulated PKC activity while
inhibiting PKC, this is much less than the previously observed 40% increase in PKC
activity following 15m PTH(1-34) activity. Further experiments will be necessary to
account for the discrepancies observed between the results of the analogue experiments
and the kinase inhibition experiments, as well as to further examine the effect of the PKC
inhibitor peptide at preventing later increases in PKC activity.
The effect of PTH on Npt2a mRNA expression during selective pathway
inhibition was examined next using relatively specific pathway inhibitors. As shown in
Figure 15A, the inhibition of PKA by 1µM H-89 over the course of 6.5h had no
significant effect on Npt2a mRNA expression. With PKA inhibited, PTH still produced a
decrease in Npt2a mRNA, although this effect was delayed compared to the time course
of PTH alone, indicating that PKA is important for the early phase of PTH-mediated
Npt2a mRNA destabilization. OK cells were next treated with 10µM PKCi, a selective
peptide inhibitor of PKC. As with the H-89 experiments, inhibiting PKC alone did not
affect Npt2a mRNA expression (Figure 15B). However, the partial inhibition of PKC did
not prevent the PTH-mediated decrease in Npt2a mRNA, with significant decreases still
observed at the 1h time point, and continuing to the 6h time point, with an ultimate
reduction of 55% achieved following 6h of combined PKCi and PTH treatment, similar
to what was achieved with PTH alone. While it appears that the PTH effect on Npt2a
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mRNA was not blunted by the inhibition of PKC, PKC activity assays at the 1h and 6h
time points are required to confirm these results.

Part 4: Effect of inhibition of endocytosis on PTH-mediated Npt2a mRNA destabilization
Recent studies suggest that chronic PTHR1 signaling occurs with endocytosis of
the PTH receptor producing sustained cAMP generation133. In addition to their findings
that sustained PTHR1 cAMP signaling occurs from early endosomal compartments,
Ferrandon et al. also demonstrated that blocking the endocytosis of the ligand-receptor
complex diminished the length of cAMP generation from more than 20 minutes down to
about five minutes133. To test whether this mechanism of PTH signaling influences Npt2a
mRNA expression levels, OK cells were treated for 30m with chlorpromazine (CPZ), an
inhibitor of clathrin-mediated endocytosis155, in the presence and absence of PTH for 2h.
As shown in Figure 16, inhibiting endocytosis did not blunt the effect of PTH on Npt2a
mRNA.
FIGURE 16
Figure 16: Effect of
endocytosis inhibition on
PTH-mediated Npt2a
mRNA destabilization. RTqPCR with RNA isolated
from OK WT cells treated
with either 100nM PTH(1-34)
for 2h, 40µM chlorpromazine
(CPZ) for 2.5 h, or 30m
chlorpromazine pretreatment
followed by combined PTH
and chlorpromazine for 2h.
(n=2)
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DISCUSSION

We examined the relative contribution of PTH-stimulated signaling pathways to
the destabilization of Npt2a mRNA using three different approaches: (1) PTH analogues
with relatively selective kinase-activating properties, (2) pharmacologic activators of
PKA and PKC, and (3) selective pathway inhibition during PTH treatment. The results of
these studies suggest that the signaling pathways involved in PTH-induced Npt2a mRNA
destabilization are complex and perhaps intertwined. The pharmacologic studies support
the notion that PKA signaling is more important for the early phase of the PTHstimulated decreased in Npt2a mRNA, as selective stimulation of PKA using three
approaches produced an earlier onset decline in Npt2a mRNA than did selective
stimulation of PKC (Figure 17). Use of the PTH analogues study demonstrated that
neither the PKA-specific nor the PKC-specific analogue by itself was capable of
producing the same degree of Npt2a mRNA destabilization as occurs with activation of
both by the full peptide hormone, although each analogue ultimately accomplished a
partial reduction. Interpretation of these results in hampered by the fact that neither
analogue was either completely specific or as effective in activating the designated
pathway as was PTH(1-34). Direct activators of PKA and PKC revealed more clear-cut
results, with PKA activation by 8-Br-cAMP producing a pattern of Npt2a mRNA
destabilization very similar to that of PTH(1-34), and PKC activation by PMA producing
no significant effect. Use of the selective inhibitors of PKA or PKC during PTH
stimulation produced results that were also more difficult to interpret, as neither inhibitor
was completely specific or robust in inhibiting activation of the desired pathway.
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FIGURE 17

Figure 17: Summary of effects of selective PKA or PKC activation on Npt2a mRNA.
(A) Studies in which PKA was activated (treatments with PTH(1-31) [+], 8-Br-cAMP
[*], and PTH + PKCi) are shown compared to PTH(1-34) treatment. (B) Studies in which
PKC was activated (treatments with PTH(3-34) [*], PMA [#], and PTH+H-89 [+]) are
shown compared to PTH(1-34) treatment. * and *** (according to respective symbol) are
indicative of P < 0.05 and 0.01, respectively, as determined by two-way ANOVA, versus
PTH(1-34).
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Despite these limitations, the studies do suggest a role for PKA in the early phases of
PTH-mediated Npt2a mRNA destabilization, while PKC contributes to the later
destabilization of Npt2a mRNA.
The activity assays performed are consistent with the conclusion that the two
pathways contribute differentially, depending on whether the PTH stimulation is acute or
chronic. Whereas PKA activity increased with 15m of PTH(1-34) treatment, this
activation decreased by the 2h and 6h time points, indicating an early role for PKA
signaling. PKC activity also increased within the first 15m of PTH(1-34) treatment, but
unlike PKA, continued to increase throughout the 2h and 6h time points. Taking this into
account with the fact that the relatively PKC-specific PTH analogue PTH(3-34) failed to
produce a decrease in Npt2a mRNA until the 6h time point, these results suggest a more
prominent role for PKC in long-term PTH signaling. In agreement with this conclusion,
Guo et al.51 recently established that the sustained hypophosphatemic response to PTH in
mice is dependent on the PLC signaling pathway. In transgenic mice featuring a PTH
receptor incapable of PLC activation, PTH was only able to transiently decrease serum Pi
for two days, after which the hypophosphatemic response decayed. These results support
our findings that PKC signaling contributes to the later stages of Npt2a mRNA
destabilization, but is not required for early inhibition.
It is interesting to note that Pi-depleted animals fail to produce a
hypophosphatemic response to PTH administration, despite normal activation of PKA156.
The authors of the study concluded that phosphate depletion inhibits cellular metabolic
pathways that are independent of cAMP signaling, and that inhibition of those pathways
is sufficient to completely blunt the phosphaturic actions of PTH. The signaling pathways
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affected by PTH may have a common end effector, but they also have independent
actions that may blunt the influence of the other signaling pathway, and PKA and PKC
may thus be able to independently exert downregulatory effects on Npt2a mRNA.
The studies in this chapter point to an early role for PKA and a late role for PKC,
but it appears that activation of both are essential for achieving the full decrease in Npt2a
mRNA elicited by PTH(1-34). When comparing the effects of the two truncated PTH
analogues on Npt2a mRNA versus the original effect of PTH(1-34) (Figure 13E), an
interesting dichotomy emerges. In the early phases of PTH signaling, both PTH(1-31)
and PTH(3-34) fell significantly short of decreasing Npt2a mRNA levels to the extent
that PTH(1-34) did. It is not until the later stages of PTH signaling, hours 6 and 8, that
PTH(3-34) and (1-31) appear to catch up with the decreases elicited by (1-34). Part of
PTH-induced PKA signaling is produced by sustained cAMP production following
endocytosis of the PTHR1 complex. Inhibiting PTHR1 endocytosis is known to prevent
the sustained production of cAMP in response to PTH133. We tested whether this
sustained generation of cAMP by PTHR1 endocytosis affected PTH regulation of Npt2a
mRNA by treating OK cells with chlorpromazine, an inhibitor of endocytosis, in the
absence and presence of PTH. We observed that inhibiting endocytosis failed to prevent
PTH-mediated Npt2a mRNA destabilization. Although we are unable to make any
conclusive statements regarding the contribution of internalized PTHR1 signaling to the
sustained decreased in Npt2a mRNA, these results suggest that the initial generation of
cAMP by adenylyl cyclase is sufficient for producing sustained destabilization of Npt2a
mRNA.
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These studies suggest the possibility of cross-talk between PKA and PKC, with
neither kinase working completely independently of the other. This is not the first time
studies have supported this kind of signaling mechanism in the regulation of Npt2a
expression. In studies of Npt2a protein downregulation by PTH, Cunningham et al.
proposed a cross-talk-dependent mechanism, wherein PTH stimulates PKA, which in turn
activates PKC in order to cause the ultimate endocytosis of Npt2a from the apical
membrane58. Dopamine, another phosphaturic agent, also activates both PKA and PKC in
the kidney through the D1 receptor, and has also been shown to elicit cross-talk between
the two kinases. Yu et al.157 demonstrated that dopamine-mediated inhibition of NADPH
oxidase involved cross-talk between PKA and PKCθ, with PKA activation preceding and
facilitating PKC activation, and phosphorylated PKCθ mediating the resultant inhibition
of NADPH oxidase. The activity assays we performed with the PKA and PKC inhibitors
support this conclusion, in that H-89 prevented both basal PKA and PKC activity, as well
as PTH-induced PKA and PKC activity, and thus PKA most likely plays an additional
role in the activation of PKC mediated by PTH.
Although PKA-dependent PKC signaling is one possible explanation for the
contribution of the signaling pathways we observed, it does not fully explain the
signaling mechanisms involved in PTH regulation of Npt2a mRNA. Whereas
Cunningham et al. observed that inhibiting PKC completely abolished the
downregulation of Npt2a, we observed preservation of PTH-induced Npt2a mRNA
degradation during the inhibition of either pathway. Another possibility aside from kinase
cross-talk is that there are multiple ultimate mediators of the mRNA destabilization, and
PKA and PKC are each responsible for activating one arm of the multi-pronged cascade.
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This idea was demonstrated by Azarani et al.158, who showed that both PKA and PKC
could independently decrease NHE3 activity. In this case, Npt2a mRNA destabilization
could be accomplished through the activation of several RNA-binding proteins that
function as an RNA destabilizing complex, with individual RNA-binding proteins
modified by either PKA or PKC. The current studies do not provide distinction between
these two possibilities of kinase cross-talk or independent effects, and thus additional
studies are required to further define the mechanisms of intracellular signaling leading to
destabilization of Npt2a mRNA.
The PKA and PKC pathways are the primary signaling pathways activated by
PTH in the proximal tubule, but there are additional pathways also activated by PTH that
should be considered. For example, cAMP activates PKA, but it also activates another
signaling molecule, Epac. Activated Epac is a demonstrated regulator of some PTHsensitive proximal tubule transporters, including NHE3159. To rule out the potential
involvement of Epac in Npt2a mRNA regulation, a cAMP analogue that selectively
activates Epac was used to treat OK cells. In agreement with previous studies that found
that selective Epac activation had no effect on Npt2a protein expression and function58,
we found no evidence of Epac involvement in the regulation of Npt2a mRNA expression.
The data presented within this chapter provide compelling evidence for the
importance of both PKA and PKC signaling in the degradation of Npt2a mRNA, but the
lack of total congruity in the results from the three approaches precludes making absolute
conclusions on the relative roles of each pathway. Of the three studies performed to
examine the relative contribution of the PKA and PKC signaling pathways towards Npt2a
mRNA destabilization, two of the studies suggest a role for late PKC involvement, but
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the direct PKC activation study did not support this conclusion. In the direct activation
studies, we used PMA to directly activate PKC. We observed no effect of PMA treatment
on Npt2a mRNA expression, and these results conflict somewhat with the PTH(3-34) and
PKCi studies. However, phorbol esters have been shown to change OK cell morphology
by inducing cell rounding, and these changes are not observed with PTH treatment80.
Thus, while the conflicting PMA data obfuscates the implication for PKC involvement
indicated by the other studies, unintended consequences of the use of PMA may be
responsible for the lack of an observable effect on Npt2a mRNA. PMA also bypasses
activation of PLC, which may activate non-PKC pathways that contribute to Npt2a
mRNA destabilization. Additionally, we did not examine intracellular calcium signaling
with the use of PMA nor did we measure stimulated PKC activity, and the absence of the
initial calcium spike may have prohibited full activation of PKC, thus preventing PKCmediated regulation of Npt2a mRNA.
We are proposing that the upregulated activity and/or expression of an RNAbinding protein is the mechanism behind chronic downregulation of Npt2a by PTH. From
the studies herein, we found that the PTH-mediated decrease in Npt2a mRNA is
dependent upon both PKA and PKC signaling. Both of these pathways contribute to the
end result of mRNA degradation, and either individually or synergistically produce the
PTH effect. The dependence of the PTH-induced decrease in Npt2a mRNA on
transcription and translation suggests that PKA or PKC signaling is involved in changing
the activity and/or expression of transcription factors. Studies by Queiroz-Leite et al.160
determined that PTH-mediated PKA and JAK/STAT signaling in OKP cells, a clonal cell
line of the OK WT cell, changes the profile of transcription factor expression in the
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nucleus. This change in transcription factor expression may change the expression of
RNA-binding proteins that in turn influence Npt2a mRNA stability. Given that we know
post-translational modifications produced by PKA and PKC activation mediate Npt2a
mRNA destabilization, the next goal in examining the aspects behind regulation of Npt2a
mRNA by PTH was to identify downstream targets that have undergone changes in
phosphorylation in response to PTH, and how those targets relate to the control of
phosphate reabsorption in the proximal tubule. Further studies addressing this hypothesis
of the regulation of RNA-binding proteins in the proximal tubule by PTH and their
effects on Npt2a mRNA are outlined in Chapter VI.

CONCLUSION
We conclude that PKA mediates the early phase of PTH-mediated Npt2a mRNA
destabilization, whereas chronic down-regulation requires both PKA- and PKC-mediated
mechanisms through an intricate, concerted interplay between PKA and PKC signaling,
and possibly additional pathways.
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CHAPTER VI

SPECIFIC AIM III: CHARACTERIZATION OF THE PTH-RESPONSIVE
PHOSPHOPROTEOME IN THE PROXIMAL TUBULE

Background

Activation of the PTH receptor initiates several intracellular signaling cascades,
and the actions of kinases and exchange factors produce the collective PTH response.
Although much work has been done over the past several decades to elucidate the end
results of PTH stimulation in the proximal tubule, the molecular pathways leading to the
downregulation of phosphate transport are still poorly understood. We previously
established in Chapter IV that PTH destabilizes Npt2a mRNA in a rapid fashion that is
dependent on both transcription and translation. In Chapter V, we determined that both
PKA and PKC signaling contributes to this effect, with PKA acting early and PKC acting
late to promote Npt2a mRNA decay. While PTH-induced signaling pathways may
produce upregulated gene expression of specific RBPs, another possibility is that PKA
and PKC directly phosphorylate decay-promoting RBPs that have a high constitutive
turnover rate. If the latter were true, inhibiting transcription and translation would blunt
PTH-mediated destabilization of Npt2a mRNA. Given the results of the two previous
aims, we hypothesize that PTH-mediated destabilization of Npt2a mRNA is dependent on
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increased phosphorylation and/or expression of an RNA-binding protein. Presently, the
goal of the current chapter is to characterize the PTH-responsive phosphoproteome
within the proximal tubule, and characterize PTH-responsive RNA-binding proteins that
may mediate Npt2a mRNA decay.

Regulation of mRNA expression
Regulation of mRNA, and in particular mRNA stability, is a dynamic process that
involves a host of auxiliary factors, from the cradle to the grave. As soon as transcription
begins in the nucleus, the emerging RNA strand is met by proteins that modify the
transcript. Capping enzymes add a modified base, 7-methyl guanosine, to the 5’ end of
the transcript, a spliceosome complex removes introns, and the 3’ end undergoes an
addition of a polyadenosine (poly(A)) tail that enhances stability161. Along with the
recruitment of nuclear export proteins, this initial association of proteins with the RNA
strand forms a particle termed a ribonuclearprotein (mRNP) complex. The mRNP
assembly is then exported to the cytoplasm as an mRNA strand that is comprised of a
capped 5’ untranslated region (UTR), followed by a coding region, and finally a 3’ UTR
with a poly(A) tail.
Most mRNA regulatory elements are found within the 5’ and 3’UTR regions,
where the primary and secondary structures serve as scaffolds for the recruitment of
various protein complexes. In the cytoplasm, unique proteins interact with both ends of
the mRNA strand. At the 5’ end, the protein eIF4E binds the modified guanosine cap161.
The 3’ poly(A) tail is bound by the poly(A) binding protein (PABP). The initiation factor
eIF4G forms a link between eIF4E and PABP, thus joining the 5’ and 3’ ends of the
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transcript and forming a closed-loop conformation. This closed conformation protects the
ends of the transcript from exonucleolytic decay and enhances overall transcript stability.
The 5’UTR has mostly been implicated in the control of translation, whereas the 3’UTR
serves several other critical functions, including nuclear export, cytoplasmic localization,
translational efficiency, and mRNA stability162.
More than 90% of human genes undergo alternative splicing, and the highest site
for variation produced by alternative splicing is within the 3’UTR, highlighting its
importance in producing the highly differential spatial expression profiles of proteins
within various tissues throughout the body163. Structures within the transcript itself, such
as the poly(A) tail or specific nucleotide motifs, are termed cis-acting sequence elements,
and these elements dictate the profile of trans-acting factors, such as miRNA and RNAbinding proteins (RBPs), that bind mRNA and determine the fate of the mRNA strand.
For instance, sequences within the 3’UTR may dictate the types of location-determining
RBPs that regulate mRNA localization162, and these distinct localization patterns allow
for more rapid and controlled responses to external stimuli. Apart from miRNAs and
RBPs, another major category of trans factors that regulate mRNA stability is comprised
of small non-coding RNAs (ncRNAs) such as small interfering RNAs (siRNAs) and
microRNAs (miRNAs). These small molecules regulate gene expression through partial
or complete complementary binding to sequences within mRNA. Near-complementary
binding typically prevents translation from occurring, whereas full-complementary
binding induces degradation through the recruitment of the Argonaute RNA-induced
silencing complex (RISC)161.
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Protein-induced mRNA decay
RNA destabilization leads to the decay of the mRNA strand, which can be
initiated either from the ends of the transcript or within the strand via endonucleolytic
cleavage161, and the rate of RNA decay is modulated by the specific cohort of RBPs
interacting with the message. One of the most well characterized family of RBPs that
determine mRNA stability bind to a specific cis-element called adenylate-uridylate rich
elements (AREs)161. These ARE-binding proteins, or ARE-BPs, typically bind a AUUUA
pentamer in a U-rich region anywhere from 40 to 150 nucleotides long164. ARE-BPs can
bind a spectrum of AREs, however, including ones that lack the canonical AUUUA
motif165. Signifying its importance as a regulator of gene expression, bioinformatic
studies suggest that 5 to 8% of human genes contain ARE sequences166.
HuR is a member of well-known family of proteins that bind AREs and promote
message stabilization, either through competitive binding with destabilizing trans factors,
or through enhanced interactions of PABP with the poly(A) tail to prevent
deadenylation161. Other ARE-BPs, including the AU-rich factor 1 (AUF1) and the KH
splicing regulatory protein (KHSRP), promote mRNA destabilization161. Although AUF1
is most classically known as an RNA destabilizer, new evidence suggests that under
certain conditions, AUF1 can also act as a stabilizer or a translational repressor167.

The 3’ UTR of Npt2a mRNA
Not much is known about the trans factors that regulate Npt2a mRNA stability.
Moz et al. previously demonstrated that hypophosphatemia increases Npt2a expression
through stabilization of Npt2a mRNA via increased protein binding to a 71-nucleotide
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cis-acting instability element in the 3’UTR117,168. However, little work has been published
since those studies that detail RBP regulation of Npt2a mRNA in response to
physiological stimuli. The predicted secondary structure for the opossum 3’ UTR of
Npt2a is shown in Figure 18, based on either the minimum free energy of the structure
(Figure 18A), or the thermodynamic favorability (Figure 18B). Several RNA-binding
proteins are predicted to interact with the 3’ UTR of Npt2a mRNA, including ones that
modulate stability. As shown in Figure 18C, these RBPs include ELAVL1 (a synonym
for HuR), the ARE-BP that confers stability to a transcript, as well as KHSRP, an AREBP that is known to destabilize transcripts. Many of the RBP binding sites also overlap,
indicating the possibility of competitive binding for those RBPs.

The PTH-responsive phosphoproteome
Little is known about the range of downstream targets regulated by PTH signaling
in the proximal tubule. The earliest studies of the PTH-responsive phosphoproteome
looked at phosphorylation events at the apical membrane that governed the regulation of
phosphate transport in response to PTH169. The present studies outlined in this chapter
seek to characterize the cell-wide phosphorylation events that occur in response to PTH,
and how those changes may relate to the downregulation of Npt2a mRNA. In Chapter IV,
we established that PTH induces a rapid decrease in Npt2a mRNA, with an approximate
50% decrease after 2h of PTH stimulation. In Chapter V, we determined that during the
early phase, PKA signaling appeared to predominate, while PKC signaling played a more
prominent role during the later phases. We have therefore chosen to study the PTHresponsive phosphoproteome at 30m and 2h. While we are proposing that altered activity
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FIGURE 18

Figure 18: Predicted secondary structure of the 3’ UTR of Npt2a mRNA. The
sequence for the 3’ UTR of opossum Npt2a (obtained from Ensembl.org) was submitted
to the Vienna RNA Websuite program for computational analysis170,171. (A) Predicted
secondary structure based on minimum free energy. (B) Predicted secondary structure
based on the thermodynamic favorability of the minimum total base-pair distance to all
structures in the ensemble. Color scale indicates likelihood of base-pair interaction or, for
unpaired bases, likelihood of being unpaired, with blue representing unlikely and red
representing highly likely. (C) Map of likely RBP interactions with the 3’ UTR of Npt2a
mRNA, as predicted by the RBPDB (RNA-Binding Protein Database) server172.
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and/or expression of an RBP is the mechanism behind PTH-mediated destabilization of
Npt2a mRNA, we have not yet identified any potential effectors of the decay response.
Characterizing the PTH-responsive phosphoproteome will not only provide candidate
RNA-destabilizing targets for further exploration of the aspects behind Npt2a mRNA
destabilization, but it will also provide novel hypothesis-generating data for research
projects to come.
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METHODS AND MATERIALS

Materials: Bovine PTH (1-34) was purchased from Bachem Biosciences Inc. (King of
Prussia, PA). Magnetic RNA-binding protein immunoprecipitation (Magna RIP) kits
were obtained from EMD Millipore (Billerica, MA). Antibodies against KHSRP and
Roquin-2 were purchased from Novus Biologicals (Littleton, CO). All other reagents
were obtained from Sigma (St. Louis, MO) unless otherwise indicated.

PTH-D1 mouse model: Kidneys from PTH-D1 and age-matched control mice, as
described in Chapter IV Methods, were used for IHC analysis of KHSRP and Roquin-2
expression.

Cell culture: Studies involving differential RBP expression in response to PTH were
conducted using the Opossum Kidney (OK) cell line. OK cells were cultured exactly as
previously described in Chapter IV. Unless otherwise noted, cells were grown to 90-95%
confluence on 6-well plastic plates (Corning, Tewksbury, MA) and serum-starved
overnight prior to treatment.

Protein determination: Protein concentration of OK cell nuclear-free lysates was
determined using a bicinchoninic acid (BCA) protein kit (Sigma) using bovine serum
albumin (BSA) as a standard.
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Liquid chromatography-mass spectrometry: OK WT cells were grown to confluence in
T-75 flasks, serum starved overnight, and treated with either 100nM PTH(1-34) for 2h or
MEM (as control). Following treatment, cells were washed twice with ice-cold PBS and
lysed in a 5mM Tris 50mM mannitol buffer, pH 7.4, containing protease and phosphatase
inhibitor cocktails. Cells were homogenized by 15 passes through a 26G needle, and
nuclei were discarded by centrifuging the samples at 750*g for 5min and retaining the
supernatant for mass spectrometry analysis. Phosphoproteomic analysis of control and
PTH samples was performed with the assistance of Dr. Michael L. Merchant173,
University of Louisville, who enriched for phosphopeptides using sequential enrichment
with TiO2 and IMAC resin, and identified proteins using high sensitivity, high mass
accuracy LCMS. Resulting proteins were identified according to their UniProt ID
symbol174.

Gene identification and pathway analysis: UniProt ID symbols were individually
converted to gene names through Uniprot.org174. The functions of specific RNA-binding
proteins identified within the phosphoproteome were also determined through
Uniprot.org. Once gene names for all 1182 proteins were obtained, the gene list was
submitted to DAVID for gene ontology analysis175,176. Opossum genes not recognized by
DAVID software were converted to the orthologous human gene name (determined
through Ensembl.org177) prior to DAVID analysis. Gene ontology for the dataset was
analyzed against the dataset for the human genome.
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Computational analysis of RNA-protein interaction prediction: The likelihood of RNAprotein interaction was predicted using the RNA-Protein Interaction Prediction (RPISeq)
software from the Dobbs and Honavar laboratories
(http://pridb.gdcb.iastate.edu/RPISeq/)178,179, with opossum Npt2a 3’ UTR, KHSRP
protein, and Roquin-2 protein sequences obtained from Ensembl.org. Random Forest
(RF) or Support Vector Machine (SVM) classifiers were used to evaluate likelihood of
interaction, with 0.5 and above considered the cutoff value for a positive prediction
probability of RNA-protein interaction.

Isolation of crude membrane, crude nucleus, and cytosol: Cells were treated as described,
washed once with ice-cold PBS, and lysed in lysis buffer consisting of 5mM Tris 50mM
Mannitol. Cells were lysed by passing the suspension through a 26G needle 15 times.
Homogenate was spun at 1500*g for 5 min, and pellet was collected for crude nuclear
fraction. Supernatant was transferred to a fresh tube and spun at 30,000*g for 45 min to
pellet crude membranes (including the plasma membrane and endoplasmic reticulum),
and the supernatant of spin two was collected as the cytosolic fraction.

Sucrose density gradient centrifugation: Cells were grown to confluence in T-75 flasks
and treated with low phosphate media or regular phosphate media for 24h. Cells were
rinsed twice with ice-cold PBS and scraped in a buffer containing 5mM Tris-HCl, 50 mM
mannitol, and phosphatase and protease inhibitors. Cells were homogenized with 10
passes through a 26G needle, spun at 1500*g for 5 min, and pellet discarded. 1 mg of
protein was loaded on top of a sucrose gradient made of stacked 200μL layers of 5 to
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40% sucrose in Tris-Mannitol buffer. Gradients were centrifuged using a SW55 rotor at
32,400 rpm for 16h. One 150 μL fraction was first collected from the top, followed by
200 μL fractions for the rest of the gradient. Specific cell compartment fractions were
determined by blotting each fraction for markers of the endoplasmic reticulum, plasma
membrane, cytosol, and nucleus. Once the location of compartments was identified,
fractions corresponding to a cell compartment were pooled, and 100 μL of each pooled
fraction was combined with 33 μL Laemmli buffer and heated at 95°C for 5 min. 125 μL
of each sample were loaded per lane onto a 10% polyacrylamide gel.

Western blot analysis: Following protein estimation, equal amounts of membrane,
nuclear, or cytosolic proteins were heated in Laemmli buffer at 95°C for 5 minutes to
denature proteins. Protein samples were separated by SDS-PAGE and analyzed by
Western blot, as previously described in Chapter IV.

RNA-binding protein immunoprecipitation (RIP): RIP experiments were performed
according to manufacturer’s protocol. Briefly, OK WT cells were grown to 95%
confluence in T-75 flasks (Corning, Tewksbury, MA), and serum-starved overnight prior
to treatment. Flasks were treated with 100nM PTH(1-34) or MEM (as control) for 2h.
Afterwards, cells were rinsed twice with ice-cold PBS and scraped into 10 mL of PBS.
Cells were collected by spinning at 1500 rpm for 5min at 4°C, and the supernatant was
discarded. Cell pellets were resuspended in an equal pellet volume of RIP lysis buffer
containing protease and RNase inhibitors. Lysates were incubated on ice for 5min and
then stored overnight at -80°C. The following day, magnetic beads were prepared for
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immunoprecipitation by incubating the beads with 5 μg antibody of interest or isotype
IgG for 1.5h at room temperature, then washed three times. RIP lysates collected
previously were quickly thawed and centrifuged at 14,000 rpm for 10min at 4°C. 100 μL
of the supernatant was transferred to each antibody-beads complex. 10 μL of the
supernatant was saved at -80°C as input for comparison of RT-PCR results. All of the
tubes containing the antibody-beads complexes were incubated with rotation overnight at
4°C. The next day, beads were washed 6 times with cold RIP wash buffer. Following the
final wash, each immunoprecipitate was resuspended in 150 μL of Proteinase K Buffer
consisting of 117 μL RIP wash buffer, 15 μL 10% SDS, and 18 μL proteinase K. All
tubes were incubated at 55°C for 30min with shaking to digest the protein. Supernatants
were collected and transferred to a new tube, and processed for RNA isolation.

Isolation of RNA: RNA from digested RIP samples was isolated exactly as previously
described in Chapter IV, from the addition of phenol:chloroform:isoamyl alcohol onward.

Reverse transcription and real-time PCR: RT-qPCR was performed on RNA isolated
from RIP experiments exactly as previously described in Chapter IV. PCR reactions were
performed in triplicate, and the three data points averaged to obtain one Ct value per
sample. IP efficiency was determined by comparing the fold difference (calculated as
described in Chapter IV Methods) of IP conditions to IgG controls performed for each
condition.
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Immunohistochemistry: IHC was performed as described in Chapter IV. Antibodies
against KHSRP and Roquin-2 were used at a dilution of 1:1000. Secondary biotinconjugated antibodies were also used at a dilution of 1:1000.

Statistics: Data are shown as mean ± SE. The n values represent the number of
independent experiments. P values were calculated by Student’s t-test or by one- or twoway ANOVA, followed by Bonferroni analysis using GraphPad Prism software. A P
value <0.05 was a priori considered statistically significant.
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RESULTS

Part 1: The PTH-responsive phosphoproteome
Through proteomic analysis, we identified 1183 individual proteins whose
phosphorylation significantly changed in response to PTH. The gene names of 1139
phospho-proteins were recognized by DAVID for functional analysis. DAVID mapped
852 proteins out of the1139 submitted to one or more biological process categories.
DAVID analysis identified 245 categories of biological processes regulated by PTH. As
shown in Figure 19A, processes involved in transcription and its regulation were the top
biological processes altered by PTH, followed by intracellular signaling and phosphate
metabolism. 204 unique proteins, or 17.2% of the PTH-responsive phosphoproteome,
were identified as effectors of transcription or regulators of transcription. Perhaps not
surprisingly, protein localization (77 proteins) and amino acid phosphorylation (70
proteins) are also major biological processes regulated by PTH. Processes governing cell
cycle and macromolecular metabolism rounded out the top ten biological processes
modified by PTH.
DAVID also mapped 723 proteins to 96 categories of cellular location (Figure
19B). The cellular compartment identified as having the most proteins (253) regulated by
PTH is comprised of non-membrane-bounded organelles, which is defined as a structure
of distinct morphology and function, but not bound by lipid bilayer. Types of structures
included in this category are ribosomes, the cytoskeleton, and chromosomes. Other major
cellular components regulated by PTH include the cytoskeleton (160 proteins),
intracellular organelle lumens (148 proteins), and the nuclear lumen (136 proteins).
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FIGURE 19
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Figure 19: PTH-responsive phosphoproteome. Proteins identified as having undergone
significant changes in their phosphorylation status in response to PTH were subjected to
DAVID analysis. (A) Top 10 biological processes of the phosphoproteome. (B) Top
cellular components of the phosphoproteome.

98

Of the 1139 phospho-proteins identified by DAVID gene ontology analysis of
molecular functions, 68 proteins were categorized as having RNA-binding properties. 30
of the phospho-RBPs underwent significant increases in their phosphorylation status
within 30m of PTH treatment (Table 1, pages 101-102). 16 of the RBPs only exhibited
increased phosphorylation after 2h of PTH treatment (Table 2, page 103), and the other
22 RBPs underwent significant decreases in their phosphorylation status in response to
PTH (Table 3, page 104). Within the category of fast-responding RBPs, PRPF31, a
ubiquitously expressed pre-mRNA splicing factor180, underwent the largest increase in
phosphorylation status. SRRM2, another splicing factor174, also had increased
phosphorylation after 30m PTH, and was the most increased of all the RBPs at the 2h
time point.
Whereas most RBPs experienced increased phosphorylation within 30m of PTH
treatment, some only responded after 2h of PTH stimulation. Of the delayed-responding
RBPs, RPL7, a regulatory protein of the translation apparatus, experienced the biggest
increase in phosphorylation. Also prominent in the delayed-responding RBP category
was the cap-recognition protein eIF4A1, which also experienced a significant increase in
phosphorylation after 2h of PTH treatment.
The third category of RBPs consists of 22 RBPs that underwent a decrease in
phosphorylation in response to PTH (negative-responding RBPs). Several underwent a
transient dephosphorylation in response to 30m PTH, but regained their basal
phosphorylation after 2h. Included in that category are ZC3HAV1, PDCD11, and
SCAF1, proteins involved in viral mRNA degradation, ribosomal RNA biogenesis, and
pre-mRNA splicing, respectively. NANOS3 experienced a transient dephosphorylation
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with 30m PTH, but after 2h had phosphorylation levels 33 times greater than basal
phosphorylation. EIF4G3, or eukaryotic translation initiation factor gamma 3, is a
component of the protein complex that recruits ribosomes to mRNA, and in response to
PTH, underwent a transient decrease in phosphorylation that increased above baseline
following 2h PTH treatment.
RNA-binding proteins serve several different functions, and only a subset of
RBPS influence RNA stability. Preliminary functional analysis of the phospho-RBPs
identified two RBPs that are known to modulate mRNA stability. The first, RC3H2,
responded early to PTH treatment, with a significant increase in phosphorylation within
30m of PTH that was sustained after 2h. RC3H2, more commonly referred to as Roquin2, is an RBP that promotes constitutive mRNA decay181. RPISeq software178,179 predicted
through the use of Random Forest (RF) or Support Vector Machine (SVM) classifiers
that Roquin-2 potentially interacts with the 3’UTR of Npt2a mRNA, with an SVM
classifier value of 0.93. The second phospho-RBP of interest, KHSRP, only experienced
an increase in phosphorylation after 2h of PTH. KHSRP is a multi-functional RBP, and
one of its primary functions is to regulate mRNA stability182,183. RPISeq also predicted
that KHSRP can interact with the 3’UTR of Npt2a mRNA, with an RF classifier of 0.85
and an SVM classifier of 0.73. Predictive values above 0.5 are considered a positive
indicator of protein-RNA interaction. As an initial analysis of the PTH-responsive RBPs,
we chose to further explore the roles of KHSRP and Roquin-2 in the PTH response and
their potential interaction with Npt2a mRNA.
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Part 2: Regulation of KHSRP and Roquin-2 Expression by PTH
Computational analysis of the PTH-responsive phosphoproteome suggests that
two of the PTH-responsive RBPs, KHSRP and Roquin-2, are capable of interacting with
the 3’UTR of Npt2a mRNA. To confirm the expression of KHSRP and Roquin-2 in the
proximal tubule, cell fractions prepared from OK cells treated with and without PTH
were subjected to Western blot analysis. As shown in Figure 20A, KHSRP expression
was found in crude membrane, nuclear, and cytosolic fractions. KHSRP nuclear
expression was also found to significantly increase in response to PTH. IHC of control
and PTH-D1 mouse kidneys also confirmed proximal tubular expression of KHSRP
(Figure 20B), and showed a nuclear expression pattern as well as cytosolic and/or
intracellular compartment expression with distinct prominence on the basolateral side of
the cell. Increased nuclear expression of KHSRP was observed in the PTH-D1 kidneys in
comparison to control, supporting the results of the OK cell Western blot study.
To strengthen the hypothesis that PTH-regulated KHSRP expression and activity
is related to the control of phosphate transport by PTH, and not another PTH-regulated
function, we next treated OK cells with low phosphate media, a stimulus for Npt2a
upregulation. We reasoned that if KHSRP is involved in destabilization of Npt2a mRNA
expression and its expression increased with PTH, then low phosphate should decrease its
expression. Following 24h treatment with low phosphate media, cell compartments were
isolated by sucrose density gradient centrifugation, and KHSRP expression analyzed by
Western blot. We observed decreased expression of KHSRP in the plasma membrane and
endoplasmic reticulum in response to 24h low phosphate, and increased KHSRP
expression in the cytosol (Figure 20C). Interestingly, we also observed multiple
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FIGURE 20

Figure 20: KHSRP expression in the
proximal tubule. (A) Crude membrane,
crude nucleus, and cytosol fractions were
prepared from OK cells and Western blot
analyses performed for KHSRP (top band,
“K”) and β-actin (bottom band, “β”). Images
shown are representative (n = 4). * is
indicative of P < 0.05 versus control (0 h), as
determined by one-way ANOVA. Percentages shown indicate relative changes of
expression within each cell compartment. (B) Immunohistochemical staining for
KHSRP in control FVB and PTH-D1 mouse kidneys. (C) Plasma membrane (P.M.),
endoplasmic reticulum (E.R.), nucleus, and cytosol fractions were prepared from OK
cells treated with regular or low phosphate media, and blotted for KHSRP.
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immunoreactive bands at different molecular weights than the typical 75kD band.
Although we cannot conclusively comment on the functional importance of these
potential variants, the presence of these bands with distinct cell compartment expression
profiles indicates the possibility that KHSRP is expressed as several splice variants, with
their functional role dependent on cellular distribution.
In addition to examining the effect of PTH on KHSRP expression, we also studied
the response of Roquin-2 to PTH treatment. As shown in Figure 21A, we identified
Roquin-2 in the crude membrane, crude nucleus, and cytosolic fractions. PTH treatment
over the course of 2h did not significantly affect crude membrane Roquin-2 expression.
However, in both the nuclear and cytosolic fractions, Roquin-2 expression increased.
When OK cells were treated with low phosphate media for 24h, Roquin-2 expression
decreased in both the endoplasmic reticulum and nuclear fractions (Figure 21B). As with
KHSRP, we found that the molecular weight of Roquin-2 differed between cell
compartments, with a smaller immunoreactive band observed in the E.R. fraction as
opposed to the Roquin-2 band in the nuclear fraction, again indicating the potential
presence of compartment-specific splice variants.

Part 3: Interaction of KHSRP and Roquin-2 with Npt2a mRNA
We have established that the expression of both KHSRP and Roquin-2 is
responsive to PTH and ambient phosphate, physiological regulators of proximal tubular
phosphate reabsorption. Computational analysis predicts that both proteins can interact
with the 3’ UTR of Npt2a mRNA, but the expression studies alone do not provide
conclusive evidence for a role of KHSRP or Roquin-2 in the destabilization of Npt2a
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FIGURE 21

Figure 21: Roquin-2 expression in the proximal tubule. (A) Crude membrane, crude
nucleus, and cytosol fractions were prepared from OK cells and Western blot analyses
performed for Roquin-2 (top band, “R”) and β-actin (bottom band, “β”). Images shown
are representative (n = 4). * is indicative of P < 0.05 versus control (0 h), as determined
by one-way ANOVA. Percentages shown indicate relative changes of expression within
each cell compartment. (B) Plasma membrane (P.M.), endoplasmic reticulum (E.R.),
nucleus, and cytosol fractions were prepared from OK cells treated with regular or low
phosphate media. Fractions were separated by sucrose density gradient centrifugation,
separated by SDS-PAGE, and Western blotted for Roquin-2.
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mRNA. Therefore, to determine whether KHSRP and/or Roquin-2 interact with Npt2a
mRNA, we next performed RNA-binding protein immunoprecipitation (RIP) assays,
wherein an intact mRNP complex is pulled down with an antibody specific for an RBP,
followed by RNA isolation and RT-qPCR to identify transcripts associated with the RBP.
As shown in Figure 22A, immunoprecipitation of KHSRP pulled down Npt2a mRNA in
comparison to isotype IgG IP. Immunoprecipitation of Roquin-2 also showed that Npt2a
mRNA was pulled down with Roquin-2 (Figure 22B). While immunoprecipitation of
KHSRP and Roquin-2 from PTH-treated cells showed less fold enrichment for Npt2a
mRNA than in KHSRP and Roquin-2 IPs from control cells, normalization of Npt2a
mRNA from the immunoprecipitation to Npt2a mRNA in the input will be necessary to
determine whether more or less Npt2a mRNA is associated with the two RBPs in
response to PTH treatment.

109

FIGURE 22

Figure 22: Interaction of KHSRP and Roquin-2 with Npt2a mRNA. IP of KHSRP or
Roquin-2 followed by isolation of RNA and RT-qPCR was performed as described in
Methods. Immunoprecipitation of (A) KHRSP (n=3) and (B) Roquin-2 (n =1) showed
that Npt2a mRNA was pulled down with both RBPs.
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DISCUSSION

For the first time, we have characterized the cell-wide phosphorylation events that
occur in response to PTH. We were able to categorize 1139 out of the 1182 proteins that
underwent significant changes in phosphorylation over the course of 2h PTH treatment,
and we discovered that PTH, along with being a major regulator of proximal tubule ion
transport, is also a major regulator of both transcription and translation. Almost one-fifth
of the downstream targets of PTH are proteins involved in the process of transcription or
its regulation. This category of biological processes altered by PTH was by far the most
affected biological process, distantly followed by the categories of intracellular signaling
cascade (8.3%), phosphate metabolic process (6.9%), and protein localization (6.5%). As
expected in characterizing the PTH-responsive phosphoproteome, we also found that
PTH was also a major regulator of protein phosphorylation.
We found that PTH was also a major regulator of translation, as we identified 68
RNA-binding proteins whose phosphorylation status changed in response to PTH.
Because DAVID was only able to map 812 of the submitted 1182 proteins to a molecular
function, the number of RBPs regulated by PTH may be higher. Some of the RBPs
modified by PTH-mediated signaling include members of the translation complex, such
as EIF4G3, EIF2A, and EIF4A1. EIF4G3 is the linker protein between the 3’ and 5’ ends
of mRNA, forming a closed-loop configuration that protects the mRNA from degradation
by exonucleases161. PTH induces a transient dephosphorylation of EIF4G3, potentially
affecting the stability of the closed-loop configuration and overall stability of the mRNP
complex.
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The destabilization of Npt2a mRNA in response to PTH is a specific event, and
likely related to modified RBP interaction with the 3’UTR. The destabilizing effect of
PTH on Npt2a mRNA is a rapid process, as PTH decreases the level of Npt2a mRNA
expression by 50% from over 8 hours under basal conditions to just over 2 hours. We
focused on exploring the roles of Roquin-2 and KHSRP in mediating this process, as both
were predicted to interact with the Npt2a 3’UTR.
KHSRP (hnRNPK-homology (KH)-type Splicing Regulatory Protein) is a multifunctional RBP, and is involved not only in regulating mRNA stability, but also in
mRNA localization and trafficking, pre-mRNA splicing, and miRNA maturation184.
KHSRP mediates the rapid shortening of the poly(A) tail accompanied by 3’-5’
endonucleolytic decay by recruiting exosome machinery, including the enzymes poly(A)
RNase (PARN), exosome component EXOSC2, and DCP2, the decapping
enzyme183,185,186. KHSRP contains four KH domains, and all four domains are necessary
for interaction with the decay-promoting exosome187. It is through these KH domains that
KHSRP recognizes AREs in 3’UTRs of transcripts184. While the 3’UTR of Npt2a mRNA
lacks the canonical AUUUA element, it nonetheless has type III AREs within U-rich
regions, and two predicted binding sites for KHSRP. Both predicted binding sites for
KHSRP within the 3’ UTR of Npt2a mRNA consist of the sequence GUCC, with one of
the elements starting at base 7 (from the 3’ end) and the other starting at base 176172. The
first binding site is situated very closely to the 3’ end of the mRNA (Figure 18C), which
is predicted to be right next to the poly(A) tail of the mature transcript. This proximity in
theory would facilitate the actions of recruited deadenylases to promote mRNA decay,
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although it remains to be seen whether the 3’ binding motif is important for promoting
destabilization.
Much less is known about the function of Roquin-2 as an mRNA decay factor in
comparison to the studies that have examined KHSRP-mediated RNA degradation. Loss
of function mutations in Roquin are known to lead to a severe lupus-like autoimmune
syndrome in mice188,189. Roquin-2 and its paralog Roquin-1 have redundant functions in
T cells, and Roquin-2 can fully compensate for the loss of Roquin-1189. Because of this
prominent systemic role of Roquin-2, the vast majority of Roquin-2 studies have focused
on its effects on the immune system, and no studies to date have examined the role of
Roquin-2 in the kidney. However, several studies have examined the mechanisms of
RNA binding and promotion of decay by Roquin-2, and these mechanisms of mRNA
regulation are likely to be conserved in other tissues. Roquin-2 recognizes and binds
3’UTR cis-elements referred to as constitutive decay elements (CDEs), which are a
conserved class of stem-loop motifs typically found in regulators of development and
inflammation181. Upon binding, Roquin-2 induces mRNA decay by promoting a
deadenylase complex181. Roquin-2 has two binding sites for RNA – one that recognizes
stem-loop motifs, and another that recognizes double-stranded RNA – and both are
required for promoting RNA decay190. We could not identify the conserved CDE stemloop motif in the opossum 3’ UTR of Npt2a, but we did find a CDE motif in the mouse
3’UTR. While interaction with RNA requires a preserved CDE consensus in a stem-loop
motif, recent studies suggest that Roquin-RNA binding is more dependent on secondary
structures and non-sequence-specific contacts, implying that a broader spectrum of RNAs
than previously thought may interact with the decay factor191.
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The studies within this chapter provide evidence that KHSRP and Roquin-2 are
potential modulators of Npt2a mRNA stability. We showed that Npt2a mRNA was pulled
down with both KHSRP and Roquin-2, which strongly suggests that both RBPs interact
with the Npt2a transcript. Additionally, KHSRP and Roquin-2 expression is modulated
by known regulators of Npt2a expression. Western blot showed a 10-fold increase in the
nuclear expression of KHSRP after 2h PTH. This increase was also observed in the
nuclei of PTH-D1 mouse proximal tubules in comparison to age-matched control mice,
as determined through immunohistochemistry. While PTH treatment increased the
nuclear expression of KHSRP, treatment of OK cells with low phosphate media, a
stimulus for Npt2a upregulation, decreased both the plasma membrane and endoplasmic
reticulum expression of KHSRP, and increased the cytosolic expression. Perhaps more
interesting than the changes in expression are the differences in the molecular weight of
KHSRP dependent on cellular location. Normally a 75 kDa protein, the predominant
KHSRP band in both the plasma membrane and cytosolic compartments was around 40
kDa. In the cytosolic fraction, low phosphate treatment stimulated an increase in KHSRP,
and the appearance of a doublet in only the low-phosphate-treated condition suggests an
increase in KHSRP phosphorylation. We also observed a shift in molecular weight in the
plasma membrane compartment in response to low phosphate, from 40 kDa up to 75 kDa.
These differences in the molecular weight of KHSRP likely indicate the expression of
KHSRP splice variants, with potentially varying functions based on cell distribution. In
the human genome, there are 10 known protein-coding splice variants of KHSRP177,192.
However, further studies are required to properly interpret the functional significance of
these changes in the OK cell.
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The changes in Roquin-2 expression in response to PTH and low phosphate
differed slightly from those of KHSRP. Whereas PTH induced only nuclear increases in
KHSRP expression, Roquin-2 expression in response to 2h PTH increased in both the
cytosolic and nuclear compartments by 342% and 207%, respectively. Separation of OK
cell compartments by sucrose density gradient centrifugation following low phosphate
treatment showed decreased expression of Roquin-2 in the E.R. and nucleus in response
to 24h low phosphate. As observed with KHSRP, different molecular weights for
Roquin-2 were found in the E.R. and nucleus. The typical band for Roquin-2 in the OK
cell is approximately 55 kDa, which is the size found in the nucleus, but E.R. Roquin-2 is
approximately 35 kDa. Again, these results may imply that Roquin-2 is expressed as
several different splice variants, with differential functions of the Roquin-2 variants based
on organelle location. Human Roquin-2 is known to be expressed as 7 different proteincoding splice variants177,192, and it is likely that opossum Roquin-2 is expressed as several
splice variants as well.
The studies regarding KHSRP and Roquin-2 expression in response to stimuli that
regulate Npt2a expression are intriguing, and warrant further study to determine whether
the interaction of those two RBPs with Npt2a mRNA serves to regulate Npt2a
expression. Both KHSRP and Roquin-2 display an overall increase in expression in
response to PTH and an overall decrease in expression in response to low phosphate. This
inverse relationship to Npt2a expression indicates that KHSRP and Roquin-2 may act as
destabilizing trans-factors for the Npt2a transcript. Interestingly, KHSRP modulates PTH
mRNA decay rates in the parathyroid gland in response to changes in serum calcium or
phosphate. This occurs through the interaction of KHSRP with type III AU-rich elements
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in the PTH 3’UTR, which does not contain the classical AUUUA pentameric motif164,182.
These are the same putative KHSRP-binding motifs found in the 3’UTR of Npt2a, and
this relationship may indicate that KHSRP has a broader systemic role in the regulation
of calcium and phosphate homeostasis.
We have shown that KHSRP and Roquin-2 are responsive to PTH, with changes
in both phosphorylation and expression. However, protein phosphorylation can either
increase or decrease the activity of a protein, and we cannot make any conclusive
statements about whether phosphorylation of Roquin-2 and KHSRP by PTH signaling
upregulates or downregulates their decay-promoting function. Nothing is currently
known about how post-translational modifications such as phosphorylation affect
Roquin-2 activity. Several studies have, however, examined KHSRP activity in response
to phosphorylation events. Known KHSRP phosphorylation events are induced by both
the MAPK p38 and Akt/PKB pathways193. Phosphoproteomic analysis showed that PTH
induces KHSRP phosphorylation at S181. S181 is within the K1 domain, one of the four
KH domains required for binding RNA and recruiting exosomes. Although the functional
significance of this particular modification is unknown, there are several studies that have
addressed the effect of the phosphorylation of the neighboring S193 residue on KHSRP
function. Akt mediates S193 phosphorylation, which promotes the unfolding of the K1
domain, leading to decreased ARE binding and accumulation in the nucleus193–195.
Although we have not addressed the change in KHSRP function induced by PTH, the
phosphorylation of S181, which is also within the K1 domain, potentially has the same
destabilizing effect on the domain structure as the phosphorylation of S193. Therefore,
PTH may decrease KHSRP activity. While this action would typically stabilize KHSRP
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target transcripts, several studies have shown that KHSRP can also mediate mRNA
stabilization. Because we have not performed in vitro degradation assays of Npt2a
mRNA in the presence and absence of KHSRP, we cannot currently make any conclusive
statements about the role of KHSRP in regulating Npt2a mRNA stability. Further
experiments are required to define the exact function of KHSRP and Roquin-2 in
promoting Npt2a mRNA decay.

CONCLUSION

We conclude that PTH is a major regulator of transcription and translation in the
proximal tubule. The RNA-binding proteins KHSRP and Roquin-2 interact with Npt2a
mRNA, and are potential mediators of PTH-induced mRNA destabilization.
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CHAPTER VII
DISCUSSION: BROADENED BASES AND FUTURE DIRECTIONS

The major impact of the work described within this dissertation lies in the
establishment and description of an additional and alternative pathway for the regulation
of Npt2a expression by PTH in the renal proximal tubule. As Npt2a expression is a major
determinant of renal phosphate handling, total body phosphate homeostasis, and serum
phosphate levels, the elucidation of newer mechanisms for the regulation of Npt2a by
PTH holds promise for novel applications in clinical medicine. Because serum phosphate
levels correlate with cardiovascular risk, understanding the determinants of serum
phosphate may have important implications for the prevention and treatment of
cardiovascular disease, the major cause of death in this country.
In Chapter IV, we discovered that PTH post-transcriptionally regulates Npt2a
expression through destabilization of the Npt2a transcript, an effect that was dependent
on both transcription and translation. In Chapter V, we observed that both the PTHinduced PKA and PKC pathways contribute to PTH-mediated Npt2a mRNA
destabilization. PKA activation appears to produce early changes in downstream effectors
that provide sustained downregulation of Npt2a mRNA, and PKC activation produces
later effects that promote mRNA decay after the initial period of PKA-induced
destabilization. Chapter VI described the cell-wide phosphorylation events that occur in
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response to PTH. We were able to identify two PTH-responsive RBPs, Roquin-2 and
KHSRP, that bind to Npt2a mRNA and potentially regulate its stability in response to
PTH.
From these studies, we propose the following model of PTH-induced Npt2a
destabilization (Figure 23): PTH stimulation of the PTH receptor activates both the PKA
and PKC signaling pathways. PKA actions produce early and sustained downstream
effects that lead to Npt2a mRNA destabilization, whereas PKC signaling contributes
downstream signaling that acts during the latter phase of destabilization to sustain the
phosphaturic effects of PTH. These signaling events lead to the increased expression and
phosphorylation of Roquin-2 and KHSRP, which target Npt2a mRNA to expose the
3’UTR and alter the stability of the basal Npt2a mRNP complex. Binding of KHSRP
and/or Roquin-2 destabilizes the complex and promotes decay, potentially through
exosome or decapping enzyme recruitment, followed by either deadenylation,
exonucleolytic cleavage, endonucleolytic cleavage, or some combination thereof. Thus,
we conclude that PTH post-transcriptionally regulates Npt2a expression through PKAand PKC-dependent alteration of the stability of the Npt2a mRNP complex, promoting
mRNA decay.
Although we have provided evidence to support this conclusion, there are
additional experiments that will be necessary to confirm our findings. While we have data
that show that both Roquin-2 and KHSRP bind to Npt2a mRNA, and that both RBPs are
responsive to physiological stimuli that regulate phosphate reabsorption, we have not
conclusively shown that they mediate Npt2a mRNA decay in response to PTH. To
determine their contribution to PTH-mediated Npt2a mRNA destabilization, knockdown
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studies of Roquin-2 and KHSRP should be performed. If either or both RBPs are
involved in regulating Npt2a mRNA decay in response to PTH, then silencing their
expression should abolish or at least diminish PTH-mediated Npt2a mRNA
destabilization.

FIGURE 23

Figure 23: Proposed model of PTH-mediated Npt2a mRNA destabilization. (1)
PTH(1-34) binds the PTH receptor. (2) PTHR1 stimulation activates PKA, which
produces early phosphaturic responses to PTH. (3) PKA activation is followed by PKC
activation, which produces later effects to sustain PTH-induced phosphaturia. (4)
Activation of second messenger signaling cascades alters the expression and
phosphorylation status of the RBPs Roquin-2 and KHSRP. (5) Altered RBP composition
of the Npt2a mRNP complex through differential binding/recruitment activities of
Roquin-2 and/or KHSRP interrupts the closed-loop conformation, producing an unstable
Npt2a mRNA complex, which leads to (6) exosome recruitment (potentially) and Npt2a
mRNA decay.

120

Also of interest in further exploring the contribution of Roquin-2 and KHSRP to
the suppression of Npt2a expression are the changes in the cellular distribution of the two
RBPs, and how those changes affect mRNA decay. We observed significant nuclear
expression of KHSRP in response to PTH, and significant cytosolic and nuclear
expression of Roquin-2. While some studies suggest that phosphorylation of KHSRP at
different sites from the PTH-responsive serine residue promotes nuclear retention of the
RBP and decreased mRNA destabilization, in neither OK cells nor mouse proximal
tubules we did not observe a coordinate decrease in the cytosolic expression of KHSRP
in response to PTH, suggesting that PTH-induced phosphorylation may produce different
effects on KHSRP activity than has been previously reported. Roquin-2 expression, on
the other hand, displayed a time-dependent increase in both the cytosol and the nucleus.
Nothing is currently known about the effects of phosphorylation on Roquin-2 activity,
and thus it would be beneficial to construct phosphorylation-deficient and -mimicking
mutants of both KHSRP and Roquin-2 and examine how that alters the PTH responses
regarding Npt2a mRNA in the proximal tubule.
In addition to looking at the functional significance of Roquin-2 and KHSRP
phosphorylation, future studies directed towards identifying the kinase responsible for
their phosphorylation in response to PTH will further clarify the contribution of the PKA
and PKC pathways to Npt2a mRNA decay. Our current studies suggest that the rapid and
sustained stimulation of Roquin-2 phosphorylation may be in response to early PKA
activity, whereas the later activation of KHSRP may be due to the prolonged signaling
generated by PKC. Phosphoproteomic analysis identified residue S181 on KHSRP and
residues T543 and S549 on Roquin-2 as being phosphorylated in response to PTH. Using
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ScanSite to identify canonical kinase motifs within KHSRP and Roquin-2196, we found
several kinases that were predicted to phosphorylate the particular residues responsive to
PTH. Within Roquin-2, T543 is a canonical binding site for both Akt and 14-3-3 mode 1,
whereas S549 is a putative phosphorylation site for GSK3 kinase, Erk1 kinase, and p38
MAP kinase. Within KHSRP, S181 is predicted to be phosphorylated by calmodulindependent kinase 2, CDK motif 1, and CDK motif 2. Although neither PKA nor PKC
were predicted to directly modify the PTH-responsive sites on the RBPs, it is possible
that PTH stimulates phosphorylation of other residues within the protein that were not
detected by mass spectrometry, as both PKA and PKC were predicted to phosphorylate
other residues within Roquin-2 and KHSRP. It is also possible that PTH stimulates the
indirect activation of the aforementioned kinases through the activation of PKA and
PKC. Further clarification would come from exploring the contribution of other PTHactivated signaling pathways, both dependent and independent of PKA and PKC
activation, to the overall effect on RBP activity and Npt2a mRNA stability.
As we identified KHSRP as a potential mediator of PTH-induced Npt2a mRNA
degradation, it is interesting to note that KHSRP has been previously characterized as a
regulator of PTH mRNA stability in the parathyroid gland. The further exploration of the
role of KHSRP in regulating proximal tubular phosphate transport may allow for the
discovery of common mechanisms for the regulation of mineral metabolism throughout
multiple tissues in the body. While we chose to initially study the involvement of
Roquin-2 and KHSRP in PTH-mediated Npt2a mRNA destabilization, other RBPs in the
PTH-responsive phosphoproteome were also categorized by DAVID analysis as
regulators of mRNA stability. These proteins include ZFP36L1, HNRNPD, and
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HNRNPU. While HNRNPD and HNRNPU are ubiquitously expressed and not likely to
be specific for PTH-induced Npt2a mRNA regulation, ZFP36L1 is another candidate
protein that could possibly be involved in the regulation of Npt2a mRNA. Like KHSRP,
the phosphorylation status of ZFP36L1 was increased after 2 hours of PTH stimulation,
and it was also predicted by RPISeq to interact with the 3’ UTR of Npt2a mRNA. Thus,
future experiments examining the potential role of ZFP36L1 in modulating Npt2a mRNA
stability may yield promising results. Although we have already identified two PTHresponsive RBPs that may regulate Npt2a mRNA stability, there are multiple RBPbinding sites within the 3’UTR of Npt2a mRNA, and differential regulation of several
RBP interactions, not just one, may be required for the full decay effect.
The fact that over 200 regulators and effectors of transcription are altered in
response to PTH lends credence to our model of PTH-induced protein expression
mediating Npt2a mRNA destabilization. While the decay response is rapid, PTHmediated downregulation of Npt2a mRNA and protein expression appears to reach a
steady state. Chronic PTH stimulation greatly diminishes the apical expression of Npt2a,
but it does not eliminate it entirely. Similarly, chronic PTH stimulation greatly diminishes
Npt2a mRNA levels, but again, this effect reaches maximal suppression around 12h,
achieving a new steady state of expression. We have identified the cellular responses that
mediate the initial reduction in Npt2a mRNA, but further work remains to elucidate the
chronic changes in the Npt2a mRNP complex that contribute to a rate of Npt2a mRNA
decay equal to the rate of Npt2a mRNA synthesis.
We have answered several questions about the mechanisms behind the chronic
downregulation of proximal tubular phosphate reabsorption by PTH, but we have also
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generated many more. A century’s worth of research on the processes underlying the
regulation of phosphate homeostasis has brought us to our current understanding, and yet
the field of knowledge still remains incomplete. Within these chapters, however, we have
expanded that knowledge base through the identification of a novel mechanism of Npt2a
regulation by PTH, and we have provided a basis for continuing to explore the
physiological mechanisms underlying proximal tubular phosphate reabsorption.
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APPENDIX

Proteins
KHSRP – hnRNPK-homology (KH)-type Splicing Regulatory Protein
Na+/K+-ATPase – sodium potassium ATPase
NBC1 – sodium-bicarbonate cotransporter isoform 1
NHE3 – sodium-hydrogen exchanger isoform 3
NHERF-1 – sodium-hydrogen exchanger regulatory factor isoform 1
Npt2a – type IIa sodium-phosphate cotransporter
Npt2c – type IIc sodium-phosphate cotransporter
PiT-2 – inorganic phosphate transporter isoform 2
PTHR1 – PTH receptor type I
RC3H2 – Roquin-2
ZFP36L1 – Zinc Finger Protein 36, C3H1 Type-Like 1

Cell signaling
AC – adenylyl cyclase
AKAP79/150 – A kinase anchor protein
Akt – serine/threonine protein kinase; also referred to as Protein Kinase B
cAMP – cyclic adenosine monophosphate
Epac – exchange protein activated by cAMP
ERK1/2 – extracellular-signal-regulated kinase
FGF23 – fibroblast growth factor isoform 23
GPCR – G-protein-coupled receptor
IP3 – inositol triphosphoate
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MAPK – mitogen-activated protein kinase
PDE - phosphodiesterase
PKA – protein kinase A
PKC – protein kinase C
PLC – phospholipase C
PTH – parathyroid hormone
PTHrP – PTH-related peptide

Molecular biology
RBP – RNA-binding protein
CDE – constitutive decay element
PDZ - post synaptic density protein (PSD95), Drosophila disc large tumor suppressor
(Dlg1), and zonula occludens-1 protein (ZO-1)
UTR – untranslated region
mRNP – ribonucleoprotein complex composed of mRNA and associated RBPs
PABP – poly(A) binding protein
eIF4G - eukaryotic translation initiation factor 4 gamma
eIF4E - eukaryotic translation initiation factor 4E
ncRNA – non-coding RNA
siRNA – small interfering RNA
miRNA – micro RNA
RISC - RNA-induced silencing complex
ARE – AU-rich element
ARE-BP – AU-rich element binding protein
HuR – Human antigen R
ELAVL1 - embryonic lethal abnormal vision-like 1; synonym for HuR
RIP – RNA-binding protein immunoprecipitation
IP - immunoprecipitation
eIF4A1 - eukaryotic translation initiation factor 4A1
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Methods & Reagents
8-Br-cAMP – 8-bromo-cyclic adenosine monophosphate
Act D – actinomycin D
ANOVA – analysis of variance
BBM – brush-border membrane
BLM – basolateral membrane
BSA – bovine serum albumin
Chx - cycloheximide
CM – crude membrane
CPM – counts per minute
CPZ - chlorpromazine
DAB - 3,3'-Diaminobenzidine
DAG - diacylglycerol
DAVID - The Database for Annotation, Visualization and Integrated Discovery
FVB – background strain of transgenic PTH-D1 mice
H-89 – pharmacologic inhibitor of PKA
HRP – horse radish peroxidase
IHC - immunohistochemistry
OK – opossum kidney
PKCi – PKC inhibitor peptide
PMA – phorbol myristate acetate
PTH-D1 – transgenic mouse strain featuring parathyroid-specific cyclin D1
overexpression
RF – Random Forest
RPISeq - RNA-Protein Interaction Prediction
RT-qPCR – reverse transcription quantitative polymerase chain reaction
SDS-PAGE - sodium dodecyl sulfate polyacrylamide gel electrophoresis
SVM – Support vector machine
TTBS – Tween-tris-buffered saline
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